CN106901871A

CN106901871A - Intraocular lens with one or more extentions

Info

Publication number: CN106901871A
Application number: CN201510975072.2A
Authority: CN
Inventors: 不公告发明人
Original assignee: EYEBRIGHT (BEIJING) MEDICAL TECHNOLOGY Co Ltd
Current assignee: EYEBRIGHT (BEIJING) MEDICAL TECHNOLOGY Co Ltd
Priority date: 2015-12-23
Filing date: 2015-12-23
Publication date: 2017-06-30
Anticipated expiration: 2035-12-23
Also published as: CN106901871B

Abstract

The present invention relates to medical treatment device, the medical treatment device particularly for treating cataract, especially, the intraocular lens for preventing and/or treating After Cataract, more specifically, the intraocular lens with one or more extentions it include:A) main body;B) annular episome, is connected with intraocular implants' phosphor bodies.

Description

Intraocular lens with one or more extentions

Technical field

The present invention relates to medical treatment device, the medical treatment device particularly for treating cataract, especially, for preventing and/or The intraocular lens of After Cataract is treated, more specifically, the intraocular lens with one or more extentions.

Background technology

A variety of causes is for example aging, heredity, local dystrophia, immune and metabolic disorder, wound, poisoning, radiation etc., can Cause crystalline lens metabolic disorder, cause crystallins to be denatured and muddiness occurs, referred to as cataract, as population in the world is aged Change, cataract incidence and ill population are all being continuously increased.Cataract has become global first diseases causing blindness, In the whole world totally 4000 ~ 45,000,000 blind persons, because of cataract, blinding person accounts for 46%.At present, just there is cataract patient 6,700,000 in China, often Year newly-increased cataract blind person about 1,300,000, because cataract causes blurring of vision even to be blinded, causes huge to cataract patient Life inconvenience and pain.

It is to treat cataract most efficient method at present that intraocular lens is changed by performing the operation.However, after cataract operation Patient still suffers from a significant problem：Posterior capsular opacification（PCO）.The crystalline substance that post gelating time is remained mainly due to postcataract Shape body epithelial cell（Lens Epithelium Cells, LECs）Along the propagation of rear cyst wall, migration, fiber metaplasia and formed , it is the most common complication that affects one's power of vision after cataract operation.Its incidence of disease is 30 ~ 50% in adult（In 5 years）, wherein The patient for having 20%~30% blinds once again because of inverse position method, and the patient for having 43% performs the operation again because of inverse position method, After cataract in children The incidence of disease is 100%.When the Lens Epithelial Cells of postcataract residual occur cell growth along preceding cyst wall, capsule is mixed before producing It is turbid, referred to as " ACO ".

In addition it is postoperative it also occur that inflammatory reaction, such as infectious endophthalmitis, uveitis after intraocular lens IOL implantation Deng.Therefore for cataract patient implantable artificial crystalline lens after, carry out the treatment of medicine.Using steroids and non-hormone anti-inflammatory agent Eye droppings treatment, prevention of postoperative uveitis and fibroplasia are carried out, acute iridocyclitis, upper sclerotitis, anaphylaxis is prevented Keratitis and macular edema etc..Coordinate ofloxacin eye drops simultaneously, suppress bacterial conjunctivitis, keratitis, dacryocystitis, postoperative The infection such as infection.Treated by the way of eye droppings inflammation exist intraocular chemical concentration periodically it is higher, fluctuate it is larger, it is impossible to stabilization Sustained anti-microbial anti-inflammatory, due to needing the operation of patient and coordinating, the inconvenience of life is increased to patient, increases patient burden

Prior art treats established PCO by laser Posterior capsulotomy, and laser Posterior capsulotomy may product some unfavorable feelings Condition, due to the capsule destruction natural cover for defense after incision, causes postoperative complication, including intraocular implants' bulk damage, and postoperative intraocular pressure is raised, Huang Spot oedema, detachment of retina and Dislocated IOL etc., therefore, for PCO, people strive to find prevent its formed Approach and method

The method of prevention at present and/or treatment PCO is typically started with terms of several：The design of intraocular lens, operation technique side The improvement of formula, artificial lens carry the methods such as medicine, laser Posterior capsulotomy.

In the design aspect of intraocular lens, sharp, square edges are used in intraocular lens optic, such as U.S. is special Profit 6162249 and 6468306, has proved to be a kind of method that can effectively reduce post gelating time, because this be designed to resistance Gear Lens Epithelial Cells are moved between the rear surface of intraocular lens and rear capsule（Referring to the article of Buehl et al., Journal Of Cataract and Refractive Surgery, volume 34,1976-1985.In in recent years, the industry has many work to use In the IOL with sharp rear edge is formed, to produce sharp discontinuous bending part in rear cyst wall, such as Nishi U.S. is special Profit 5171320, Woffinden United States Patent (USP) 5693093, CN1310625C, CN1684643, CN102711666A, CN201888856U。

Similar design also includes patent CN1856281, and it discloses a kind of intraocular lens, it sets in optic periphery There is sharp hypotenuse, the segmental arc that its described sharp bevel edge the joint portion restriction at link position between button loop and optical section prolongs Stretch；Patent CN2626458Y, a kind of intraocular lens of careless mistake is it is characterized in that the of common intraocular lens's non-optic portion Two faces edge increase by a raised step, are grown with the migration for blocking epithelial cell, after reaching prevention implantation of artificial lens The problem of post gelating time；CN2717403Y devises a kind of Sigma intraocular lens, by the side of intraocular lens's optical lens Edge design is processed as the wedge shape being inwardly recessed, and is also a kind of sharp hypotenuse, after preventing similar to Greek alphabet Σ from the side While capsule is muddy, dazzle is prevented.

This area research reduces the risk of post gelating time also by crystalline lens material design is changed.Referring to " the third of Mandle Olefin(e) acid intraocular lens causes less post gelating time than PMMA, siloxanes IOL " ophthalmology news, the phase of volume 14 15, page 23 （1996）.And " relation between artificial lens biomaterial and posterior capsule opacification " of Ursell et al.（Relationship Between Intraocular Lens Biomaterials and Posterior Capsule Opacification. J. Cataract. Refract. Surg.,24:352-360,1998）, and patent CN1188178C is by changing crystalline lens material Material mode reduces posterior capsular opacification risk, including front surface layer and the rear superficial layer different from front surface layer.

In intraocular lens carries prescription formula, a kind of mode carry it is medicinal prevent post-operation inflammatory, and microorganism infection, be each Class antibiotic, steroidal anti-inflammatory medicine and NSAIDs, such as patent CN2531755Y " slow-releasing agent carried artificial lens " are open A kind of slow-releasing agent carried artificial lens, it punches on artificial lens button loop, is used to filled with sustained release agent medicine prevent in hole Intraocular inflammation after implantation of artificial lens；CN104434811A discloses a kind of medicine being embedded on intraocular lens's button loop and delays Microballoon is released, effectively preventing and treating postcataract microorganism infection, antagonism inflammatory reaction, prevention and suppression After Cataract.It is another It is the mitosis for LEC being eliminated by carrying lens epithelial cells target agent or suppressing epithelial cell to plant, including anti-generation Class medicine and mitotic inhibitor are thanked, suppressed the medicine immunotoxin and cytotoxin of inflammatory reaction, suppressed cell and cell Medicine, the inducing cell apoptosis medicine of epimatrix adhesion.If the United States Patent (USP) 5620013 of Bretton is " on the remaining crystalline lens of destruction The method of chrotoplast ", United States Patent (USP) 4918165 propose to prevent posterior capsular opacification using methotrexate (MTX)；United States Patent (USP) US5576345A Posterior capsular opacification, the also patented technology including following discloses are prevented using taxol.

Shitosan-polyacrylic acid is prepared fluorouracil nano particle preparations by patent CN100553692C, mixing Coating increases intraocular lens's biocompatibility on PMMA intraocular lenses surface, prevents the generation of PCO and ACO； , be coated in anti-cell proliferation agents on artificial lens using polymeric coating material by CN101053680B, can delay Slow release To pouch and ambitus cell, suppress the growth of Lens Epithelial Cells, prevent and treat the formation of inverse position method；Patent CN101269240B, Disclose a kind of intraocular lens of surface with anti-transforming grouth factor beta 2 antibody membrane；CN200973766 delays annular pharmaceutical Release carrier to be fixed on the outside of intraocular lens ambitus, slow release suppresses lens epithelial cell proliferation medicine after implantation Thing, prevents the generation of inverse position method；Patent CN103099706 discloses a kind of intraocular lens for preventing and/or treating inverse position method, It fixes trypsase on lenticular surface, can optionally destroy crystalline in lens capsule when being implanted in lens capsule Body epithelial cell, prevents the generation of post gelating time.

Although suitable on these theoretical methods, medicine toxicity in itself can cause serious complication, intraocular poison secondary Significant reaction, poor specificity, or curative effect is not high, and there are medicine excessive velocities, discharges unstable situation, while it cannot be guaranteed that All of artificial Lens Epithelial Cells in pouch are killed, these Technical investment clinical practices have certain difficulty, any residual LEC final hyperplasia and may be moved on intraocular lens after pharmacy effect disappearance, ultimately result in PCO.

Surgical technique aspect, oculist understands that the crystal body cell of residual causes post gelating time, therefore in operation In always strive to improve modus operandi and reduce the residual of epithelial cell as far as possible, and its carefully remove all remaining crystalline lenses Epithelial cell, is also developed, for example to the apparatus for removing：It is white that patent CN103099705A discloses a kind of preventing and treating late coming Cataract or glaucoma（PCO）Device, lens epithelial cells can be optionally removed in operation, so as to prevent the generation of post gelating time. Although but done many effort, generally also have a considerable amount of epithelial cells and stay on the inner surface of lens capsule, this is Because epithelial cell is difficult to recognize and is often difficult to touch due to the limitation of their positions on the inner surface of lens capsule And.

In recent years, PDT or light heat therapy also attract attention in the research of field of ophthalmology.Patent WO2013/ 027222 reports the chlorophyll photosensitizer for treating disease of eye；Patent CN103083133 reports a kind of based on Jenner The retinopathy photothermal laser treatment system of rice rod；Patent WO97/33619 reports a kind of photodynamic therapy by eye and changes The method of kind eyesight；Patent WO98/25648 reports a kind of light sensitivity for preparing eye disease optical dynamic therapy medicine Compound；WO98/25610 reports a kind of green Porphyrin-Based Sensitizer medicine for treating After Cataract；In treatment is white Barrier inverse position method aspect United States Patent (USP) 5733276 discloses prophylactic laser retinopexy method.According to the method, go irradiation artificial with laser Crystalline peplos, to destroy the lens epithelial cells of residual；Patent CN100455276C coats two on intraocular lens surface TiOx nano film, lens epithelium is suppressed by the suppression and oxidation of titanium dioxide optical catalyst cell proliferation The propagation of cell.

But, traditional PDT and light heat therapy are all limited by sensitising agent and cannot treated intraocular implants Body post gelating time is widely used.The sensitising agent that traditional PDT and light heat therapy is used, including light power type is photosensitive Agent and photo-thermal type sensitising agent, are finally required for being made liquid preparation, and lesion is entered after the modes such as intravenous injection enter blood Tissue, or direct injection enters pathological tissues, and after treatment end, sensitising agent needs to discharge body by the mode such as degraded or metabolism Outward.The problems such as traditional PDT and light heat therapy are due to the security and the metabolism that need consideration sensitising agent, therefore significantly Limit the scope and species of sensitising agent selection.Although the toxic and side effect very little of PDT, the sensitising agent for being used Human body is eventually entered into, with certain toxicity.And sensitising agent cannot typically be used alone, it is necessary to other drugs or compound Collective effect, is entered in human body in the form of solution, outstanding mixed liquid or emulsion, and the compound that these interact with sensitising agent also will With certain toxicity, increase Operative risk.Further, since sensitising agent needs are internal from being injected intravenously, and require injection speed Quickly, also quickly, the organ-tissue such as sick human heart and blood vessel needs to bear sensitising agent over the course for the treatment of fast to removing speed to degree The brought discomfort of speed injection；And only when sensitising agent passes through pathological tissues, can open laser irradiation is carried out effectively Treatment, therefore to delivery time and hold time and all propose requirement higher, be that therapeutic process brings difficulty.

Prior art prevents the migration of epithelial cell by the design of intraocular lens, and then reaches prevention inverse position method Purpose, its effect is limited.Remove lens epithelial as far as possible in operative process, it is also possible to reduce the generation of inverse position method Rate, but fully erased epithelium actually is difficult with physical method, these operations need the extra time, may increase ocular tissue Damage, causing the destruction of blood-aqueous barrier increases, damage the propagation that have stimulated residual epithelium cell again；Though the IOL of sharp edges So it is proved to be able to suppress PCO, but still suffers from LEC along rear capsule and in the possibility of IOL surface migrations, such case is especially held In the case that the easy contact occurred between intraocular lens periphery and pouch and power are uneven, such as Post operation intraocular lens exists It is in rotary moving in pouch；Medicine and chemical method are have very much removing or destroying residual lens epithelial cells propagation and migration Effect, but medicine and chemical method have medicine to other tissue toxic and side effects, in the same of damaged epithelium When, also toxic damages can be produced by its hetero-organization to intraocular, this is still the failure to the problem of fine solution, additionally, also active drug The concentration duration is short, it is necessary to the problem being administered continuously；Traditional PDT and light heat therapy is all limited by sensitising agent Make and cannot be widely used in treatment intraocular lens's post gelating time.Current laser Posterior capsulotomy is still treatment After Cataract Main Means, but also bring a series of complication, including IOL is damaged, postoperative intraocular pressure is raised, CME, view Film departs from, and IOL dislocations.

Therefore, prior art can not well prevent the generation of inverse position method, at present clinically also without a kind of effective Method prevents and treats inverse position method.

The content of the invention

The present invention provide medical treatment device, particularly for treat cataract medical treatment device, especially, for prevent and/or The intraocular lens of After Cataract is treated, more specifically, the intraocular lens with one or more extentions, it can One or more treatment means such as medicine, PDT are carried to combine sharp right side intraocular lens design, intraocular lens In one, solve the problems, such as that intraocular lens's epithelial cell is difficult thoroughly removing, current inverse position method prevention can be solved and controlled Treat technical problem.

The present invention relates to medical treatment device, in particular for preventing and/or treating the intraocular lens of inverse position method, it includes：

a）Intraocular lens's main part；

b）One or more extentions, its be located in intraocular lens's main part and with intraocular lens's main part split-phase Connection, extention width is 0.05 to 3.5mm, more preferably preferably 0.1 to 1.5mm, 0.2 to 0.8mm;Extention thickness It is 0.01 to 2mm, preferably 0.01 to 1mm, more preferably 0.01 to 0.7mm,

Wherein, the interior edge of extention is more than 2mm away from intraocular lens's centre distance.

According to another kind specific embodiment of the invention, intraocular lens's main part passes through physics mode with extention Or chemical mode is combined.

According to another kind specific embodiment of the invention, physics mode is selected to be inlayed, bonds, spraying, printing, being deposited with.

According to another kind specific embodiment of the invention, chemical mode is selected from substep copolymerization shaping, grafting and modifying.

According to another kind specific embodiment of the invention, the extention is located at the rear table of intraocular lens's main part Face.

According to another kind specific embodiment of the invention, intraocular lens's main part has one or more grooves, attached Plus part is embedded into intraocular lens's main part groove.

According to another kind specific embodiment of the invention, the extention has the part of medicine or active agent. In the present invention, active agent can be that any types can be used in this artificial lenticular active agent, and it can be according to product The final use of product is selected.

According to another kind specific embodiment of the invention, intraocular lens's main part has at least two sharp edges.

According to another kind specific embodiment of the invention, in intraocular lens's main part, loop and artificial lens light are supported Learn plane at an angle；Supporting the proximal end on the rear surface of loop has square edge staircase structural model；Support the rear surface of loop Far-end there is square edge staircase structural model, wherein support loop after surface step formula structure proximal end thickness be more than distal end Place's thickness.

According to another kind specific embodiment of the invention, the square edge staircase structural model of surface far-end after support loop Step drop is highly 0.1-5 millimeters, preferably 0.1-1 millimeters, more preferably 0.2-0.5 millimeters, wherein surface step after support loop The proximal end thickness of formula structure is more than far-end thickness.

According to another kind specific embodiment of the invention, the square edge staircase structural model after loop is supported at proximal end surface Step drop be 0.1-5 millimeters, preferably 0.3-3 millimeters, more preferably 0.5-2 millimeters, wherein surface step formula knot after support loop The proximal end thickness of structure is more than far-end thickness.

According to another kind specific embodiment of the invention, the rear surface of the optical section of intraocular lens's main part is Convex spherical and its radius of curvature is in the range of 6.6 millimeters -80.0 millimeters.

According to another kind specific embodiment of the invention, the rear surface of the optical section of intraocular lens's main part Radius of curvature is the 17.8%-60.0% of the radius of curvature on the preceding surface of the optical section.

According to another kind specific embodiment of the invention, the intraocular lens is prepared by materials described below, the material Material includes the copolymer that is prepared by the polymerisable monomer copolymerization comprising esters of acrylic acid, wherein comprising esters of acrylic acid can Polymerized monomer includes hydrophilic acrylate's class monomer and hydrophobic acrylic acid's esters monomer, wherein, hydrophilic acrylate's class The mol ratio of monomer and hydrophobic acrylic acid's esters monomer is 20:80-80:20, preferably 30:70-70:30, more preferably 40:60- 60:40, the material has following properties：

A, moisture content is 5-15wt%, more preferably preferably 6-13wt%, 7-12wt% at 35 DEG C；

B, index of refraction at 35 DEG C（Hygrometric state）It is 1.49-1.54, preferably 1.49-1.53, more preferably 1.50-1.52.

According to another kind specific embodiment of the invention, hydrophilic acrylate's class monomer is selected from hydrophilic radical Acrylic ester monomer, meets following formula：

Wherein, R₁It is H or C_1-6Alkyl, preferably H or CH₃；

R₂It is straight or branched, saturation or unsaturation C_1-20Alkyl or C_6-20Aryl alkyl, or straight chain or C_6-20Heteroaryl alkane Base；

X can be O, S or NR₄, wherein R₄It is H, straight or branched, saturation or unsaturation C_1-20Alkyl or C_6-20Aryl alkyl, Or C_6-20Heteroaryl alkyl, or C_3-20Cycloheteroalkylalkyl；

R₃It is C_nH_2n+1O_m, wherein m or n is equal to 0 or selected from the integer more than 1, and m≤n, or C_3-20Cycloheteroalkylalkyl or C_3-20Cycloalkyl.

According to another kind specific embodiment of the invention, hydrophobic acrylic acid's esters monomer is selected from hydrophobic group Acrylic ester monomer, meets following formula：

Wherein, R₁It is H or C_1-6Alkyl, preferably H or CH₃；

R₅It is straight or branched, saturation or unsaturation C_1-20Alkyl or C_6-20Aryl alkyl, or C_6-20Heteroaryl alkyl, or C_6-20Cycloheteroalkylalkyl or C_3-20Cycloalkyl；

Y can be H, or Z-R₆, wherein Z there may be or not exist, and can be selected from hetero atom such as O or S,

R₆It is C_6-20Aryl alkyl, or C_6-20Heteroaryl alkyl.

According to another kind specific embodiment of the invention, hydrophilic acrylate's class monomer is selected from：Methacrylic acid hydroxyl Ethyl ester, Hydroxyethyl Acrylate, hydroxy propyl methacrylate, hydroxypropyl acrylate, vinyl pyrrolidone, methacrylic acid second Epoxide ethoxy ethyl ester, ethoxyethoxy ethyl acrylate, ethoxyethyl methacrylates, ethoxyethyl acrylate, Methoxyethyl methacrylate, acrylic acid methoxy ethyl ester, dimethacrylate (1,3 butylene glycol) ester, dimethacrylate second two Alcohol ester, polyethylene glycol methacrylate-styrene polymer, polyethylene glycol 200 dimethylacrylate（Such as AGEFLEX PEG200DMA）、 Polyethylene glycol acrylate, methoxypolyethylene glycol methacrylate, methoxypolyethylene glycol acrylate, Glycidyl methacrylate Glyceride, glycidyl acrylate, acrylic acid, methacrylic acid, 2- (trifluoromethyl) acrylic acid, phenylacrylic acid, propylene Acid amides, Methacrylamide, N hydroxymethyl acrylamide, N- methylol methacrylamides, or above-mentioned substance derivative, or The mixture of above-mentioned substance, preferably hydroxyethyl methacrylate.

According to another kind specific embodiment of the invention, hydrophobic acrylic acid's esters monomer be selected from methyl methacrylate, EMA, ethyl acrylate, butyl methacrylate, butyl acrylate, hexyl methacrylate, acrylic acid oneself The tertiary fourth of ester, isopropyl methacrylate, isopropyl acrylate, Isobutyl methacrylate, isobutyl acrylate, methacrylic acid Ester, tert-butyl acrylate, EHMA, Isooctyl acrylate monomer, isodecyl acrylate, isodecyl methacrylate, Lauryl methacrylate, lauryl acrylate, octadecyl methacrylate, octadecyl acrylate, metering system Acid -9- anthracenes methyl esters, olefin(e) acid -9- anthracenes methyl esters, cyclohexyl methacrylate, cyclohexyl acrylate, acrylate, Dimethylaminoethyl methacrylate, N, N- dimethylmethacryl amides, N, N- DMAAs, acrylic acid N, N- diethylaminos ethyl ester, methacrylic acid N, N- diethylamino ethyl ester, N tert butyl acrylamide, N- tertbutyl methyls Acrylamide, NIPA, N- isopropyl acrylamides, methacrylic acid tetrahydro furfuryl ester, acrylic acid four Tetrahydrofurfuryl ester, trifluoroethyl methacrylate, acrylic acid trifluoro ethyl ester, Hexafluorobutyl mathacrylate, hexafluorobutyl acrylate, 2- perfluoro decyls ethyl acrylate, 2- perfluoro decyls EMA, 2- (perfluoro capryl) ethylmethyl acrylate, 2- (perfluoro capryl) ethyl propylene acid esters, methacrylic acid solketal ester, acrylic acid solketal ester, acrylic acid tetrahydrochysene furan Mutter ester, THFMA, phenyl methacrylate, phenyl acrylate, methacrylic acid phenyl chlorocarbonate, acrylic acid Phenyl chlorocarbonate, phenoxyethyl methacrylate, acrylate, benzyl methacrylate, benzyl acrylate, AAEM, acetoacetyl ethyl acrylate, DAAM, diacetone methacryl Amine, allyl methacrylate, acrylate, or above-mentioned substance derivative, or above-mentioned substance mixture, it is excellent Select ethyl acrylate, phenoxyethyl acrylate.

According to another kind specific embodiment of the invention, the vitrifying of the material of preparation intraocular lens of the present invention turns Temperature（Dry state, is tested by DSC and is obtained）It is 10-35 DEG C, preferably 15-30 DEG C, more preferably 20-25 DEG C.

According to another kind specific embodiment of the invention, the extension at break of the material of preparation intraocular lens of the present invention Rate（Hygrometric state）>180%, its fracture strength（Hygrometric state）>2.5 MPa.

According to another kind specific embodiment of the invention, extention also includes at least one medicine, fluorescer and/or extremely A kind of few sensitising agent；

Wherein, medicine, fluorescer and/or sensitising agent are selected from the combination of the copolymer：

- medicine, fluorescer and/or sensitising agent participate in polymerization in the copolymer forming process；

- medicine, fluorescer and/or sensitising agent are added to copolymer material in the copolymer forming process by physical dispersion In material；

- medicine, fluorescer and/or sensitising agent are fixed on the copolymer surface with surface grafting, surface modification mode；And/or

- medicine, fluorescer and/or sensitising agent are fixed on the copolymer surface with surface coating method.

Detailed description of the invention

Intraocular lens's main part of the present invention can be any type of intraocular lens's main part known in the art Point, it includes optical component and at least one support loop composition, and wherein optical component and support loop is to be made from a different material so Multistep molding or an entirety being made up of same material afterwards.Optical component is divided into preceding surface and rear surface.Preceding surface and/or after Surface can include any optical device according to the situation of user and/or requirement, such as, selected from aspherical equipment, multifocal Equipment, double-curved surface equipment, non-dispersive equipment, change focus device, the conventional suitable various equipment of light filter plant or this area.

According to a kind of specific embodiment of the invention, the rear surface of intraocular lens's main part is by central area and Zhou Bianqu Composition, wherein Zhou Bianqu may be thicker than the edge of central area at least 0.2 millimeter, to be close to optics on the rear surface of support loop One square edge staircase structural model is set at part.The step drop of square edge staircase structural model is 0.1-5 millimeters, preferably 0.3-3 millimeters, most preferably 0.5-2 millimeters.This square edge staircase structural model is conducive to stopping the propagation of Lens Epithelial Cells Migrate to the rear surface of optical component, so as to reduce the probability of post gelating time.

According to a kind of specific embodiment of the invention, support loop and the intraocular lens optic of intraocular lens's main part are put down Face（Optical flat is vertical with optic axis）It is angled, general any suitable angle can, preferred 1-20 degree, most It is preferred that 5-10 degree.Support loop with above-mentioned angle, can guarantee that artificial crystal device when by capsule squeezing action power, optical section Part protrudes or mobile to eye rear.Support the near-end of loop（That is, support loop is near one end of optical component）, open slot is set, use As a power transmission fulcrum.When support loop be subject to periphery capsule extrude when, can with open slot be fulcrum axial rotation, without by Stress passes to optical component, so as to ensure that optical component stability within the eye.Support the distal end on the rear surface of loop（That is, prop up The one end of support loop away from optical component）Place, at least 1.5 millimeters from proximal end square edge structure places, in addition there is provided right-angle side Edge platform hierarchic structure.The step drop of square edge staircase structural model is 0.1-5 millimeters, most preferably preferably 0.1-1 millimeters, 0.2- 0.5 millimeter.Square edge staircase structural model can further stop the proliferation apoptosis of Lens Epithelial Cells rearward surface, and can be A strong point is manufactured between support loop and rear capsule, stability of the artificial crystal device in capsule is improve.In addition, when artificial brilliant When folding, this staircase structural model can cause certain space to body device between its optical component and support loop, so as to drop Low adhesion strength between them, is conducive to support loop to be opened automatically after artificial crystal device implantation.

Extention of the present invention can be by any known in the art suitable for preparing Medical Devices of the present invention（Especially ophthalmic medical Equipment, such as intraocular lens）Material prepare；Especially, by be adapted to manufacture micro-incision artificial lens with properly containing The ophthalmology medical material of water rate and suitable index of refraction is prepared.Wherein, the material for preparing extention is artificial with preparation The material of lens body may be the same or different.

According to another kind specific embodiment of the invention, extention is main functional area, is reached according to the present invention Function, do not limit the shape of extention, extention can be ring-type, square, trapezoidal, interruption or continual appendix Point, any shape such as triangle, sector, the shape of any extention for being likely to be breached function of the present invention is all in guarantor of the invention Within the scope of shield.

Extention of the invention is preferably prepared by the material containing medicine, sensitising agent and/or fluorescer, or can be with Carry medicine and（Or）Sensitising agent and（Or）Filter dye, sensitising agent is fixed on extention material internal or surface, while attached Plus part edge can be with intraocular implants' optic optical surface sharp right side in 90 °, and extention may be located at crystalline substance The preceding surface and/or rear surface of shape optic, can prevent and treat muddy preceding capsule, post gelating time and POE disease Etc. illness.

According to another kind specific embodiment of the invention, extention of the present invention includes medicine, wherein, it is described Medicine includes all kinds of antibiotic, steroidal anti-inflammatory medicine and NSAIDs, prevents post-operation inflammatory, and microorganism infection.Can also Antimetabolitas and mitotic inhibitor are carried, suppressed the medicine immunotoxin and cytotoxin of inflammatory reaction, suppressed thin The medicine of born of the same parents and extracellular matrix adhesion, inducing cell apoptosis medicine come the mitosis that eliminates LEC or suppress epithelial cell, in advance Anti- and treatment post gelating time.As Ofloxacin, ascorbic acid, aspirin, colchicin, lidocaine, nepafenac, ketone are coughed up Acid, Bromfenac, lepirudin 023 ludon, MTX, 5 FU 5 fluorouracil, taxol, adriamycin, daunorubicin, saponaretin, and Other known or unknown medicines or composition with identity function.

According to another kind specific embodiment of the invention, extention of the present invention includes sensitising agent, wherein sensitising agent It is to be activated any light-sensitive coloring agent that wave-length coverage is 300~1100 nanometers, it is preferable that activation wavelength scope is selected from 500~1000 Nanometer；Especially, activation wavelength scope is selected from 600~900 nanometers；In particular, activation wavelength scope is selected from 700~900 nanometers Or activation wavelength scope is selected from 800~1100 nanometers.Sensitising agent be selected from selected from porphyrin, porphines, chlorophyll, purpurine, fluorescein, Phthalocyanine, metal phthalocyanine, CG, tricarbocyanine, nm of gold, metal nanoparticle, metal oxide nanoparticles, metal vulcanization Thing nano-particle, metal carbides nano-particle, CNT, Graphene etc., and above-claimed cpd derivative products, or on State the catabolite of compound, or above-claimed cpd salt form, or its mixture.

According to another kind specific embodiment of the invention, intraocular lens's extention of the present invention can contaminate containing filtering Material, filter dye is selected from the compound for having filtration sexual function to particular range of wavelengths, and such as extention includes blue-light absorbers, Wherein, it is change that blue light in the range of 400~500 nm has selective filtering function to wave-length coverage that blue-light absorbers are selected from Compound.Weld class compound containing azo group in preferred molecular structure formula.The further preferably Huang of polymerizable groups Color dye composition, polymerizable groups are selected from vinyl, pi-allyl, cyclobutenyl, acetenyl, acryloxy, methacryl Epoxide, acrylamido, methacryl amido, vinyl ether, etc..

Be fixed with medicine, light on medicine, sensitising agent and/or fluorescer or extention because extention of the present invention is included Quick dose and/or fluorescer, intraocular lens's implantation latter aspect can play a part of prevention, on the other hand when the tissue Or position is subjected to laser therapy once falling ill without being performed the operation again；Specifically, the material that the present invention is provided Effect with repeat function, after the completion of a laser therapy, due to sensitising agent and is not eliminated and still exists in lesion Position, when the position occurs late coming lesion again or repeatedly, can again or repeatedly receive without multiple injection sensitising agent Laser therapy, the repeatability with treatment.Specifically, provided by the present invention for preventing and/or treating After Cataract Intraocular lens contain sensitising agent, after the intraocular lens is implanted into patient's intraocular in the cataract operation, in selected laser Under conditions of external exposure, sensitising agent is activated, and by producing the cytotoxic active oxygen of tool, or produces warm high, can kill Lens epithelial cells in dead lens capsule, reach the effect of prevention or treatment After Cataract.Specifically, people of the invention Work crystalline lens extention contains sensitising agent, with photothermy.Extention with photothermy by physics mode or Chemical mode combination lens body part, wherein physics mode are selected from and cast, inlay, bonding, spraying, printing, being deposited with；Chemistry Mode is selected from substep copolymerization shaping, grafting and modifying.The intraocular lens is in selected wavelength（Such as 300-1100 nanometers）Laser Under irradiation, capsule Lens Epithelial Cells after can killing reach effect of prevention and/or treatment After Cataract.Especially, by Prolonging the generation of light school district periphery in Lens Epithelial Cells causes inverse position method, while sensitising agent region also is located at crystal optics area periphery, Therefore, when the intraocular lens carries out photo-thermal therapy, other can not be damaged while residual Lens Epithelial Cells are killed The normal cell of regional organization, Small side effects.More particularly, because sensitising agent region is located at light school district periphery, crystal is not touched Optical imagery region, so crystal has the visible light transmissivity consistent with normal intraocular lens, without optical energy loss, does not influence Patient any scene state visual experience, free from glare situation.

Artificial lens body part of the invention and/or extention can be by any known in the art suitable for preparing this hair Bright Medical Devices（Especially ophthalmic medical equipment, such as intraocular lens）Material prepare.It is particularly preferred that by being adapted to manufacture The ophthalmology medical material with appropriate aqueous rate and suitable index of refraction of micro-incision artificial lens is prepared, and it is by acrylate Prepared by class monomer copolymerization, wherein acrylic ester monomer includes hydrophilic acrylate's class monomer and hydrophobic acrylic acid's esters list Body, wherein, the mol ratio of hydrophilic monomer and hydrophobic monomer is 20:80-80:20, preferably 30:70-70:30, more preferably 40: 60-60:40, the specific following properties of the material：

A, moisture content is 5-15wt%, more preferably preferably 6-13wt%, 7-12wt% at 35 DEG C, or even 8-11wt%, especially 9- 11wt%；

Heretofore described hydrophilic acrylate's class monomer is selected from the acrylic ester monomer with hydrophilic radical, Meet following formula：

R₁It is H or C_1-6Alkyl, preferably H or CH₃；

Hydrophilic acrylate is the esters of acrylic acid with hydrophilic radical in the present invention, and it is selected from metering system Sour hydroxy methacrylate, Hydroxyethyl Acrylate, hydroxy propyl methacrylate, hydroxypropyl acrylate, vinyl pyrrolidone, methyl-prop Olefin(e) acid ethoxy ethoxyethyl acrylate, ethoxyethoxy ethyl acrylate, ethoxyethyl methacrylates, ethioxy Ethyl ester, methoxyethyl methacrylate, acrylic acid methoxy ethyl ester, dimethacrylate (1,3 butylene glycol) ester, dimethyl allene Sour glycol ester, polyethylene glycol methacrylate-styrene polymer, polyethylene glycol 200 dimethylacrylate（Such as AGEFLEX PEG200DMA）, polyethylene glycol acrylate, methoxypolyethylene glycol methacrylate, methoxypolyethylene glycol acrylate, first Base glycidyl acrylate, glycidyl acrylate, acrylic acid, methacrylic acid, 2- (trifluoromethyl) acrylic acid, phenyl Acrylic acid, acrylamide, Methacrylamide, N hydroxymethyl acrylamide, N- methylol methacrylamides, or above-mentioned substance Derivative, or above-mentioned substance mixture.It is preferred that hydroxyethyl methacrylate.

Hydrophobic acrylic acid's esters monomer is selected from the acrylic ester monomer with hydrophobic group in the present invention, under meeting Formula：

R₁It is H or C_1-6Alkyl, preferably H or CH₃；

R₆It is C_6-20Aryl alkyl, or C_6-20Heteroaryl alkyl.

Heretofore described hydrophobic acrylic acid's ester is the esters of acrylic acid with hydrophobic group, and it is selected from first Base methyl acrylate, EMA, ethyl acrylate, butyl methacrylate, butyl acrylate, methacrylic acid oneself Ester, Hexyl 2-propenoate, isopropyl methacrylate, isopropyl acrylate, Isobutyl methacrylate, isobutyl acrylate, first Base tert-butyl acrylate, tert-butyl acrylate, EHMA, Isooctyl acrylate monomer, isodecyl acrylate, methyl-prop Olefin(e) acid isodecyl ester, lauryl methacrylate, lauryl acrylate, octadecyl methacrylate, octadecyl base Ester, methacrylic acid -9- anthracenes methyl esters, olefin(e) acid -9- anthracenes methyl esters, cyclohexyl methacrylate, cyclohexyl acrylate, acrylic acid diformazan Base amino ethyl ester, dimethylaminoethyl methacrylate, N, N- dimethylmethacryl amides, N, N- dimethyl allene acyls Amine, acrylic acid N, N- diethylamino ethyl ester, methacrylic acid N, N- diethylamino ethyl ester, N tert butyl acrylamide, N- t-butylmethacrylamides, NIPA, N- isopropyl acrylamides, methacrylic acid tetrahydrofurfuryl Ester, acrylic acid tetrahydro furfuryl ester, trifluoroethyl methacrylate, acrylic acid trifluoro ethyl ester, Hexafluorobutyl mathacrylate, propylene Sour hexafluoro butyl ester, 2- perfluoro decyls ethyl acrylate, 2- perfluoro decyls EMA, 2- (perfluoro capryl) ethyl-methyl Acrylate, 2- (perfluoro capryl) ethyl propylenes acid esters, methacrylic acid solketal ester, acrylic acid solketal ester, Acrylic acid tetrahydrofuran ester, THFMA, phenyl methacrylate, phenyl acrylate, methacrylic acid benzene Base ethyl ester, phenylethyl acrylate, phenoxyethyl methacrylate, acrylate, benzyl methacrylate, It is benzyl acrylate, AAEM, acetoacetyl ethyl acrylate, DAAM, double Acetone Methacrylamide, allyl methacrylate, acrylate, or above-mentioned substance derivative, it is or above-mentioned The mixture of material.It is preferred that ethyl acrylate and/or phenoxyethyl acrylate.

The present invention is used to prepare the material of intraocular lens, in the case of necessary, should also contain one or more additions Agent, such as crosslinking agent, ultraviolet absorber, blue-light absorbers.

The present invention can contain crosslinking agent for the material for preparing intraocular lens, wherein, crosslinking agent be selected from have two or The polymerisable monomer of two or more degree of functionality, including：GDMA, ethylene glycol diacrylate, dimethyl Acrylic acid butanediol ester, butanediol diacrylate, dimethacrylate hexylene glycol ester, hexanediol diacrylate, dimethyl Acrylic acid binaryglycol ester, diethyleneglycol diacrylate, TEGDMA, diacrylate triethylene glycol The many macrogol esters of ester, dimethacrylate, many macrogol esters of diacrylate, trimethylolpropane trimethacrylate, three hydroxyls Trimethacrylate, triethylol propane triacrylate, triethylol propane trimethyl acrylic ester, bis-phenol A glycerine double methyl methacrylate, bisphenol-A glycerine double methacrylate, Diacrylate, pentanediol dimethyl allene Acid esters, methacrylic anhydride, acrylic anhydride, N, N '-methylene-bisacrylamide, N, N '-methylenebismethacrylamide, two Vinyl benzene, or above-mentioned substance derivative, or above-mentioned substance mixture.It is preferred that GDMA.

The present invention can contain ultraviolet absorber for preparing the material of intraocular lens, wherein, it is right that ultraviolet absorber is selected from Wave-length coverage has the compound of efficient absorption function in the ultraviolet of 380 below nm.Preferred security benzophenone high Class compound and/or benzotriazole compound.The further preferably benzophenone compound and/or benzo of polymerizable groups Triazole class compounds compound, polymerizable groups are selected from vinyl, pi-allyl, cyclobutenyl, acetenyl, acryloxy, methyl Acryloxy, acrylamido, methacryl amido, vinyl ether, etc..

The present invention can contain blue-light absorbers for preparing the material of intraocular lens, wherein, it is right that blue-light absorbers are selected from Wave-length coverage is compound of the blue light with selective filtering function in the range of 400~500 nm.In preferred molecular structure formula Weld class compound containing azo group.The further preferably Yellow dye compound of polymerizable groups, polymerizable group Group is selected from vinyl, pi-allyl, cyclobutenyl, acetenyl, acryloxy, methacryloxy, acrylamido, methyl-prop Acrylamide base, vinyl ether, etc..

According to another kind specific embodiment of the invention, the present invention is by hydrophobicity for preparing the material of intraocular lens Acrylate monomer and hydrophilic acrylate monomer, optional additives such as crosslinking agent, ultraviolet absorber, blue-light absorbers etc., Obtained by polymerization methodses.Wherein, polymerization methodses are selected from polymerisation in bulk, preferably are selected from by basic body polymerization methodses.Radical polymerization Close initiator and the common radical polymerization initiator in this area may be selected, it is selected from azo-initiator, and/or peroxide Initiator, preferably peroxidating double lauroyl, double (4- tert-butylcyclohexyls) peroxy dicarbonates, peroxidating two (cetyl) The double tetradecane base esters of two carbonic esters, peroxy dicarbonate, azodiisobutyronitrile, AMBN, ABVN, peroxide Change diisopropylbenzene (DIPB), benzoyl peroxide, 2,5- dimethyl -2,5- two (t-butylperoxy) hexane, tert-butyl hydroperoxide carbonic acid - 2- Octyl Nitrites, peroxidating tertiary pentyl -2 ethyl hexanoic acid ester, peroxidating (2- ethylhexyls) carbonic acid tert-pentyl ester, 2,5- dimethyl - 2,5- double (2 ethyl hexanoic acid peroxidating) hexane, 2,5- dimethyl -2,5- di-t-butyl peroxy -3- hexins, peroxidating (2- second Base caproic acid) tert-butyl ester, 1,1- cyclohexane di-tert-butyl peroxides, new last of the ten Heavenly stems peroxide tert-butyl acrylate, tert-Butyl peroxypivalate, 2- The ethylbutane peroxycarboxylic acid tert-butyl ester, 1,1- di-tert-butyl peroxide -3,3,5- trimethyl-cyclohexanes, 3,6,9- triethyl group -3, The peroxide nonanes of 6,9- trimethyls -1,4,7- three, double (3,5,5- trimethyl acetyls) peroxide, peroxidating 2 ethyl hexanoic acid 1,1, 3,3- tetramethyls butyl ester, tert-butyl hydroperoxide -3,5,5 Trimethylhexanoic acid ester, TBHP, the tertiary butane of peroxidating two, Peroxidized t-butyl perbenzoate, tert-butylperoxyiso-propyl formic acid esters, peroxidating two (2- ethylhexyls) two carbonic esters, peroxidating Tert-butyl acetate, cumyl hydroperoxide, di-isopropylbenzene hydroperoxide, t-butylcumylperoxide, tertiary amyl peroxidating Hydrogen, or above-mentioned substance mixture.It is preferred that azodiisobutyronitrile.

The present invention has moderate moisture content for preparing the material of intraocular lens, is that artificial lens is applied to micro-incision Operation provides necessary lubricity and pliability, and the index of refraction and mechanical performance to artificial lens do not cause serious simultaneously Negative sense influences.Therefore, material of the present invention（For example prepare the material of intraocular lens）, it is under state in simulation human eye（35 ℃ Physiological saline）Saturated aqueous rate is selected from 5~15 weight %, preferably 6~13 weight %, more preferably 7~12 weight %, or even 8- 11wt%, especially 9-11wt%.

The present invention has moderate index of refraction for preparing the material of intraocular lens, is processed into equal diopter manually brilliant Shape body, can accomplish than relatively thin, so as to more suitable for micro-incision implant surgery；And overcome simultaneously index of refraction it is too high caused by Effect of dispersion, so as to avoid artificial lens from producing dazzle after being implanted into.Therefore, material of the present invention（For example prepare intraocular lens's Material）, it is under state in simulation human eye（35 DEG C of physiological saline）Index of refraction is selected from 1.49~1.54, preferably 1.49~1.53, More preferably 1.50~1.52.

The present invention has special mechanical performance for preparing the material of intraocular lens, below dry state room temperature or room temperature Stiff materials are rendered as in environment, artificial lens can be processed to；And in hygrometric state（After fully hydrated）Room temperature or simulation human eye （35 ℃）Flexible material is rendered as in environment, can be folded so as to be entered in human eye pouch by catwalk, then can Automatically, lentamente recover to artificial lens original state, and the working condition of stabilization can be kept in pouch.Therefore, this hair Bright material（For example prepare the material of intraocular lens）, its dry state glass transition temperature is selected from 10~35 DEG C, preferably 15~30 DEG C, more preferably 20~25 DEG C；Material of the present invention（For example prepare the material of intraocular lens）, it is strong with moderate mechanics machinery Degree, its hygrometric state（After fully hydrated）Elongation at break is at least 180% in room temperature environment, and fracture strength is at least 2.5 MPa, i.e., The requirement of minimal access surgery implantation can be met, intraocular lens is turn avoid and situations such as folding button loop, fracture is occurred in implantation process Occur, it is ensured that security in art.

Inventor has found can be by the selection of monomer and proportioning, and the present invention for finally giving is used to prepare manually Lenticular material can possess such as above-mentioned combination property, such as have following properties simultaneously：

B, index of refraction at 35 DEG C（Hygrometric state）It is 1.49-1.54, preferably 1.49-1.53, more preferably 1.50-1.52.Material of the present invention （For example prepare the material of intraocular lens）, the mol ratio of hydrophilic monomer and hydrophobic monomer is 20:80~80:20, preferably 25:75-75:25, preferably 30:70~70:30, preferably 35:65-65:35, preferably 40:60-60:40, more preferably 45:55~ 55:45, or even about 50：50.

The present invention is used to prepare the material of intraocular lens（It is used in particular for preparing the material of extention）One can also be entered Step includes at least one medicine, fluorescer and/or at least one sensitising agent.

According to another kind specific embodiment of the invention, the present invention includes fluorescer for preparing the material of intraocular lens When, fluorescer is fixed on final material inside or surface.The combination of fluorescer stabilization, now can be using this in final material The fluorescence that invention material has, can carry out such as medical science detection, and specifically, in crack, lamp source or Pentero are micro- Cause that material fluoresces under mirror, oculist can clearly, the suitability of clearly judgement material and cornea, due to material Cornea does not make corneal dyeing, thoroughly breaks away from exogenous cornea fluorescent dye so that carry out medical science inspection using material of the present invention Survey and any extra reagent need not be added（Including fluorescer）.

According to another kind specific embodiment of the invention, the present invention includes sensitising agent for preparing the material of intraocular lens When, sensitising agent is fixed on final material inside or surface, be implanted into diseased region by the material by performing the operation, when needing to lesion When position is treated, the laser of selected wavelength is irradiated to it；After treatment end, it is only necessary to remove laser.Due to sensitising agent It is bound in material internal or surface, it is impossible to freely enter in human body its hetero-organization via blood or other body fluid, thus it is photosensitive Agent toxicity in itself can be ignored, and the range of choice of sensitising agent is also no longer influenced by limitation.Especially, the material that the present invention is provided Material can be implanted in the tissue or position that may be fallen ill in advance with other operated eyes, on the one hand can play prevention Effect, be on the other hand subjected to laser therapy without being performed the operation again once falling ill when the tissue or position；More Especially, the material that the present invention is provided has the effect of repeat function, after the completion of a laser therapy, due to sensitising agent not It is eliminated and still exists in diseased region, when the position occurs late coming lesion again or repeatedly, without multiple injection light Quick dose can again or repeatedly receive laser therapy, the repeatability with treatment.

The present invention is used in the material for prepare intraocular lens, when the copolymerization prepared by acrylic ester monomer copolymerization Thing as copolymer material, when further including at least one medicine, fluorescer and/or at least one sensitising agent, medicine, fluorescence Agent and/or sensitising agent are selected from the combination of copolymer material：

- medicine, fluorescer and/or sensitising agent participate in polymerization in copolymer material forming process；

- medicine, fluorescer and/or sensitising agent are added to copolymer material in copolymer material forming process by physical dispersion In material；

- medicine, fluorescer and/or sensitising agent are fixed on copolymer material surface with surface grafting, surface modification mode；And/or

- medicine, fluorescer and/or sensitising agent are fixed on copolymer material surface with surface coating method.

When（1）The combination of medicine, fluorescer and/or sensitising agent and copolymer material is medicine, fluorescer and/or light Quick dose in copolymer material forming process participate in polymerization when, medicine, fluorescer and/or sensitising agent comprising polymerisable monomer material Material.

When（2）The combination of medicine, fluorescer and/or sensitising agent and copolymer material is medicine, fluorescer and/or light Quick dose when being added in copolymer material by physical dispersion in copolymer material forming process, medicine, fluorescer and/or Sensitising agent can be any suitable medicine, fluorescer and/or sensitising agent, optionally comprising polymerisable monomer.

When（3）The combination of medicine, fluorescer and/or sensitising agent and copolymer material is medicine, fluorescer and/or light Quick dose when molded copolymer material surface is fixed on surface grafting, surface modification mode, copolymer material is molded Material, but copolymer material surface include polymerizable groups.

Polymerizable groups herein can be, for example：Vinyl, pi-allyl, butylene, acryloxy, methacryl Epoxide, acrylamido, methacryl amido, vinyl ether, alkynyl, hydroxyl, sulfydryl, amino, imino group, carboxyl, acid anhydrides, Aldehyde radical, NCO, siloxy group, epoxy radicals, ring nitrogen base, etc..

When（4）The combination of medicine, fluorescer and/or sensitising agent and copolymer material is medicine, fluorescer and/or light Quick dose when molded copolymer material surface is fixed on surface coating method, copolymer material is molded material.

In one embodiment of the present invention, fluorescer of the present invention is selected from：Fluoresceins（Sodium）, cyanine fluorochrome is different Thiocyanic acid fluorescein, the rhodamine material with fluorescent characteristic, the lanthanide chelate with fluorescent characteristic, phycoerythrin（P- phycoerythrin,PE）, for example many dinoflagellate phyllochlorins of material of fluorescence are produced after enzyme effect（PerCP）, propidium iodide with And other there is launch wavelength to be based on above fluorescer at 300-850 nanometers modify or modified derivative or by above chemical combination Thing sensible load is to the fluorescer formed in nano material, or its mixture.

In one embodiment of the present invention, sensitising agent of the present invention is selected from light power type sensitising agent or photo-thermal type sensitising agent. Sensitising agent of the present invention is that the wave-length coverage of the LASER Light Source being activated is 300~1100 nanometers of any sensitising agent.It is preferred that, laser The wave-length coverage of light source is selected from 500~1000 nanometers；It is preferred that, the wave-length coverage of LASER Light Source is selected from 600~900 nanometers；It is preferred that, The wave-length coverage of LASER Light Source is selected from 700~900 nanometers or the wave-length coverage of LASER Light Source is selected from 800~1100 nanometers.

In one embodiment of the present invention, the material containing light power type sensitising agent of the invention is in selected wavelength（For example 300~1100 nanometers）Laser irradiation under, the sensitising agent in material is excited, the generation cytotoxic active oxygen of tool, can be with Diseased region cell is killed, the effect for the treatment of is reached.

In another implementation method of the invention, the material containing photo-thermal type sensitising agent of the invention is in selected wavelength（For example 300~1100 nanometers）Laser irradiation under, the sensitising agent in material is excited, and luminous energy is converted into heat, makes ambient temperature Raise to kill pathological tissues cell.DNA, RNA can be suppressed when diseased tissue area temperature reaches 43 DEG C and protein is closed Into the safety margin of normal cell is 45 DEG C, therefore in preferred scheme, the material containing photo-thermal type sensitising agent shines in laser Penetrating down to generate heat, and elevate the temperature 4~20 DEG C；In preferred scheme, the material containing photo-thermal type sensitising agent is in laser Can be generated heat under irradiation, environment temperature is raised 6~12 DEG C；In preferred scheme, the material containing photo-thermal type sensitising agent Can be generated heat under laser irradiation, environment temperature is raised 8~10 DEG C.For example rise high-temperature and be more than 38 DEG C, more than 39 DEG C, preferably It is preferably greater than 41 DEG C, preferably greater than 42 DEG C, preferably greater than 43 DEG C, preferably greater than 44 DEG C, preferably greater than 45 DEG C, excellent more than 40 DEG C Choosing is less than 55 DEG C more than 46 DEG C, preferably greater than 47 DEG C, preferably greater than 50 DEG C, preferably greater than 56 DEG C, preferably greater than 57 DEG C, excellent Select more than 58 DEG C, preferably greater than 59 DEG C, preferably greater than 60 DEG C, preferably greater than 61 DEG C, preferably greater than 62 DEG C, preferably greater than 63 DEG C, Preferably greater than 64 DEG C, preferably greater than 65 DEG C, and preferably smaller than 66 DEG C, preferably smaller than 65 DEG C, preferably smaller than 64 DEG C, preferably smaller than 63 DEG C, preferably smaller than 62 DEG C, preferably smaller than 61 DEG C, preferably smaller than 60 DEG C, preferably smaller than 59 DEG C, preferably smaller than 58 DEG C, preferably smaller than It is 57 DEG C, preferably smaller than 56 DEG C, preferably smaller than 55 DEG C, preferably smaller than 54 DEG C, preferably smaller than 53 DEG C, preferably smaller than 52 DEG C, preferably small In 51 DEG C, preferably smaller than 50 DEG C, preferably smaller than 49 DEG C, preferably smaller than 48 DEG C, preferably smaller than preferably smaller than 47 DEG C, 46 DEG C.

In another implementation method of the invention, it is adaptable to sensitising agent of the invention be selected from porphyrin, metalloporphyrin, porphines, Chlorophyll, purpurine, fluorescein, phthalocyanine, metal phthalocyanine, CG, tricarbocyanine, nanogold particle, metal nanoparticle, gold Category oxide nano-particles, metallic sulfide nano-particle, metal carbides nano-particle, CNT, Graphene etc., and The derivative products of above-claimed cpd, or above-claimed cpd catabolite, or above-claimed cpd salt form.Preferred scheme In, sensitising agent is selected from indoles simple cyanine（One methine cyanines）, indoles carbon cyanines（Cyanine dye）, the carbon cyanines of indoles two（Cyanine）, indoles Tricarbocyanine（Seven methine cyanines）, three carbon cyanine dyes, benzindole hemicyanine dye, Benzpyrole squaric acid cyanine dye, phthalocyanine, chlorophyll derive Thing, pheophytin, Phephorbide a and its derivative, chlorin e 6 and its derivative, purpurine 18, chlorin p6 And its derivative, E4 and its derivative, chlorin f and its derivative, protoporphyrin and its derivative, benzo leaf is green Porphyrin, metalloporphyrin, hematoporphyrin derivative（HpD）, Porfimer Sodium, cancer light quinoline（PSD-007）, nm of gold, nanometer tungsten oxide, Nanometer Copper sulfide, nano-iron oxide, nano nickel carbide, nanometer molybdenum oxide and other repaiied based on above sensitising agent Decorations or modified water-soluble or fat-soluble derivative.

In another implementation method of the invention, sensitising agent can be that the wave-length coverage of the LASER Light Source being activated is 400 The sensitising agent of~600nm, such as fluorescein；Sensitising agent can be that the wave-length coverage of the LASER Light Source being activated is 600~750nm Sensitising agent, such as purpurine 18；Sensitising agent can be the LASER Light Source being activated wave-length coverage be 700~900nm sensitising agent, Such as CG ICG；Sensitising agent can be the LASER Light Source being activated wave-length coverage be 800~1100nm sensitising agent, such as Nm of gold.

In another implementation method of the invention, active base is contained in medicine, fluorescer and/or photosensitizer molecule structure Group, for example：Hydroxyl, sulfydryl, amino, imino group, carboxyl, acid anhydrides, aldehyde radical, NCO, siloxy group, epoxy radicals, ring nitrogen Base, etc., can with the group on copolymer material molecular side chain occur graft reaction, photosensitizer molecule in covalent bond form together Polymer material strand is combined together, and sensitising agent is fixed on copolymer material inside or its surface, equally can not be free Into in blood or other body fluid.

In one embodiment of the present invention, when containing polymerizable group in medicine, fluorescer and/or photosensitizer molecule structure Group, for example：Vinyl, pi-allyl, butylene, acryloxy, methacryloxy, acrylamido, Methacrylamide Base, vinyl ether, alkynyl, hydroxyl, sulfydryl, amino, imino group, carboxyl, acid anhydrides, aldehyde radical, NCO, siloxy group, ring Epoxide, ring nitrogen base, etc., can be copolymerized together with the polymerisable monomer of copolymer material, medicine, fluorescer and/or Photosensitizer molecule is present in copolymer material strand in covalent bond form, and medicine, fluorescer and/or sensitising agent are fixed on In copolymer material, therefore medicine, fluorescer and/or sensitising agent toxicity in itself can be ignored completely.

In another implementation method of the invention, when medicine, fluorescer and/or sensitising agent are in the mode point such as be blended or adulterate It is dispersed in copolymer material, medicine, fluorescer and/or photosensitizer molecule and copolymer material strand are with hydrogen bond or Van der Waals force Effect is combined together, and medicine, fluorescer and/or photosensitizer molecule are bound in copolymer material, it is impossible to be freely accessible to blood In liquid or other body fluid.

In another implementation method of the invention, when medicine, fluorescer and/or sensitising agent are with surface grafting, surface modification When mode is fixed on copolymer material surface, copolymer material is selected from polymerizable copolymer material, preferably on the surface comprising life The good polymerizable groups of thing compatibility, for example：Vinyl, pi-allyl, butylene, acryloxy, methacryloxy, propylene Amide groups, methacryl amido, vinyl ether, alkynyl, hydroxyl, sulfydryl, amino, imino group, carboxyl, acid anhydrides, aldehyde radical, isocyanide Perester radical, siloxy group, epoxy radicals, ring nitrogen base, etc. wherein medicine, fluorescer and/or sensitising agent can be sent out with copolymer material Raw graft reaction, copolymer material is combined together with medicine, fluorescer and/or photosensitizer molecule in covalent bond form, medicine, Fluorescer and/or sensitising agent be fixed on copolymer material inside or its surface on, can not equally be freely accessible to blood or other In body fluid.

In another preferred scheme, the mode such as medicine, fluorescer and/or sensitising agent are to dissolve, suspended, emulsification is disperseed In other auxiliary agents（For example：Cosolvent, emulsifying agent, lubricant, hydrophilic coating, load medicine, color masterbatch, ultraviolet absorber, crosslinking agent, idol Connection agent, pH adjusting agent, antistatic additive, releasing agent, etc.）In, and be coated in the surface of copolymer material, medicine, fluorescer and/or Photosensitizer molecule is combined together with copolymer material strand with hydrogen bond or van der Waals interaction, fluorescer and/or sensitising agent It is bound in the surface of copolymer material, it is impossible to be freely accessible in blood or other body fluid.

In another preferred scheme, in order to strengthen medicine, fluorescer and/or photosensitizer molecule and copolymer material point Affinity between son, medicine, fluorescer and/or photosensitizer molecule can not change it is photoactive under the premise of carry out chemistry and change Property；Copolymer material can also carry out activation process, including but not limited to, at corona treatment, sided corona treatment, flame Reason, strong acid treatment, highly basic treatment etc..

Other polymerisable monomers of the invention can be used for be included：Butadiene, styrene, AMS, styrene sulphur Sour sodium, vinyltoluene, acrylonitrile, methacrylonitrile, α-chloroacrylonitrile, ethyl acrylonitrile, methyl vinyl ether, isopropyl Vinyl ethers, n-butyl vinyl ether, IVE, tert-Butyl vinyl ether, 2- ethylhexyl vinyl ethers, 4- hydroxyls Butyl vinyl ether, BDO divinyl ether, diethylene glycol divinyl ether, vinyl esters such as, vinyl-acetic ester, alkane Hydroxyl vinyl esters of carboxylic acids, propionate, vinyl butyrate, vinyl isobutyrate base ester, caproic acid vinyl esters, 2- ethyl saccharinic acids Vinyl acetate and vinyl base ester；Allyl chloride, methallyl chloride, dichloroethylene, vinyl chloride, PVF, difluoroethylene, Sodium vinyl sulfonate, butyl vinyl sulfonate, phenyl vinyl sulfone, methyl ethylene sulfone, N- ethenyl pyrrolidones diketone, N- Yi Xi Ji oxazolidinediones, methacrylaldehyde, acrylamide, Methacrylamide, N, N- dimethyl (methyl) acrylamide, methylol Acrylamide, N- butoxy (methyl) acrylamide, isobutoxy (methyl) acrylamide etc., etc.；Other olefinics are unsaturated Carboxylic acid and its ester such as, the dialkyl ester and trialkyl ester of binary and tricarboxylic acid (such as itaconic acid), including (the 2- second of maleic acid two Base hexyl) ester, maleic acid dibutyl ester, dimethyl fumarate, dimethyl itaconate, citraconic acid diethyl ester, aconitic acid front three Base ester, mesaconic acid diethyl ester, itaconic acid two (2- ethylhexyls) ester, itaconic acid two (2- chloroethyls) ester, maleic acid, maleic acid Acid anhydride, fumaric acid, itaconic acid；And alkene is such as, diisobutylene, 1- octenes, 1- decene, 1- hexadecylenes etc., or its mixture.

In one embodiment of the present invention, medicine, fluorescer and/or sensitising agent are polymerized with copolymer material and obtain this hair During bright material, or when material of the present invention is obtained during medicine, fluorescer and/or sensitising agent are dispersed in copolymer material, the present invention Material can be prepared by the method for comprising the steps：

1）Polymerisable monomer is mixed with optional additives such as thermal cross-linking agent, initiator, ultraviolet absorber etc.；

2）Medicine, fluorescer and/or sensitising agent are added, and dissolves it, be then polymerized.

More specifically, the present invention is for preparing the method system that the material of intraocular lens can be by comprising the steps It is standby：

1）Polymerisable monomer is mixed with thermal initiator, crosslinking agent and/or ultraviolet absorber；

2）Medicine, fluorescer and/or sensitising agent are added, it is dissolved；

3）By 2）The reaction system of acquisition is positioned in mould；

4）It is polymerized, such as water-bath polymerization；

5）It is polymerized again in drier.

In another implementation method of the invention, when medicine, fluorescer and/or sensitising agent are with surface grafting, surface modification When mode is fixed on copolymer material surface, material of the present invention can be prepared by the method for comprising the steps：

1）Polymerisable monomer is mixed with optional additives such as crosslinking agent, thermal initiator, ultraviolet absorber etc., is then polymerized, obtained To copolymer material；

2）Medicine, fluorescer and/or sensitising agent are added, and dissolves it, for example, closed medicine, fluorescer and/or sensitising agent Suitable auxiliary agent（Such as polymerisable monomer）Dissolving, is then polymerized such as glycerol polymerization or surface modification or trans-printing.

More specifically, material of the present invention can be prepared by the method for comprising the steps：

2) by 1）The reaction system of acquisition is transferred in mould；

4）It is polymerized, such as water-bath polymerization；

5）It is polymerized again in drier；

6）Dissolving medicine, fluorescer and/or sensitising agent, for example, medicine, fluorescer and/or sensitising agent are used into suitable polymerizable Monomer dissolves；

7）The system of above-mentioned acquisition is polymerized such as glycerol polymerization or surface modification or trans-printing again.

In another implementation method of the invention, when medicine, fluorescer and/or sensitising agent are fixed on surface coating method During copolymer material surface, material of the present invention can be prepared by the method for comprising the steps：

1）Obtain suitable copolymer material；

2）It is by medicine, fluorescer and/or sensitising agent, such as medicine, fluorescer and/or sensitising agent is molten with a kind of suitable solvent Solution, is coated in copolymer material surface.

The present invention can be used for manufacture medical treatment device, medical science detection dress for preparing the material of intraocular lens Put, for example：For manufacturing contact lens, Ortho-K, iris hooks, internal oculoscope, artificial cornea, cornea inner ring, pouch Tension link, intracorneal lens, Glaucoma Drainage valve, slow releasing carrier of medication, Ocular tamponades, eyeground filler, glasses, eye protection Mirror, Medical Devices lens can be used to manufacture medical treatment device when it includes therapeutic agent and/or sensitising agent（Such as treat ophthalmology The device of disease）, for example, treat the device of inverse position method（Such as treat the artificial lens of inverse position method）, or can when it includes fluorescer For manufacturing medical detection device（Resulting product is set to be detected using fluorescent characteristic, in particular, Ophthalmologic apparatus e.g., have The eyeglass of fluorescent characteristic, especially ophthalmic lens, the intraocular lens with fluorescent characteristic, contact lens, Ortho-K, Iris hooks, internal oculoscope, artificial cornea, cornea inner ring, capsular tension ring, intracorneal lens, Glaucoma Drainage valve, medicament slow release Carrier, Ocular tamponades, eyeground filler, glasses, goggles, Medical Devices lens, telescope, surveillance mirror etc.）Deng other eyes Section's equipment or consumptive material.

The invention further relates to the present invention said apparatus or equipment are being prepared for preparing the material of intraocular lens（Such as medical science Therapeutic system, medical detection device）In purposes, for example：Artificial lens, contact lens, Ortho-K, iris hooks, Internal oculoscope, artificial cornea, cornea inner ring, capsular tension ring, intracorneal lens, Glaucoma Drainage valve, slow releasing carrier of medication, intraocular Filler, eyeground filler, glasses, goggles, Medical Devices lens can be used for when it includes therapeutic agent and/or sensitising agent Manufacture medical treatment device（Such as treat the device of ophthalmology disease）, the device of inverse position method is for example treated, or when it includes fluorescer When can be used for manufacture medical detection device（Resulting product is set to be detected using fluorescent characteristic, in particular, Ophthalmologic apparatus, e.g., Eyeglass with fluorescent characteristic, especially ophthalmic lens, the intraocular lens with fluorescent characteristic, contact lens, cornea modeling Shape mirror, iris hooks, internal oculoscope, artificial cornea, cornea inner ring, capsular tension ring, intracorneal lens, Glaucoma Drainage valve, medicine Thing slow-released carrier, Ocular tamponades, eyeground filler, glasses, goggles, Medical Devices lens, telescope, surveillance mirror etc.）Deng Other Ophthalmologic apparatus or consumptive material.

Term " alkyl " used herein refers to contain 1 to 500 carbon atom or 1 to 100 carbon atom or 1 to 50 carbon Atom or 1 to 20 carbon atom or 1 to 10 carbon atom or 1 to 8 carbon atom, 1 to 6 carbon atom, 1 to 4 carbon atom Or 1 to 3 straight or branched hydrocarbon of carbon atom (unless otherwise prescribed).The representative example of alkyl include but is not limited to methyl, Ethyl, n-propyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, the tert-butyl group, n-pentyl, isopentyl, neopentyl, n-hexyl, 3- Methylhexyl, 2,2- dimethyl amyl groups, 2,3- dimethyl amyl groups, n-heptyl, n-octyl, n-nonyl and positive decyl, undecyl, Dodecyl, tridecyl, myristyl, pentadecyl, cetyl, heptadecyl, octadecyl, nonadecyl, 20 Alkyl.When the linking group between " alkyl " group is two other parts, then it is likely to be straight or branched；Example bag Include but be not limited to-CH₂-、-CH₂CH₂-、-CH₂CH₂CH(CH₃)-、-CH₂CH(CH₂CH₃)CH₂-。

Term " aryl " used herein refers to phenyl (that is, monocyclic aryl) or contains the bicyclic of at least one phenyl ring System or comprised only in aromatic bicyclic system carbon atom aromatics it is bicyclic.Bicyclic aryl can be azulenyl (azulenyl), naphthalene Base is fused to the phenyl of monocyclic cycloalkyl, monocyclic cycloalkenyl or monocyclic heterocycles base.The phenyl that bicyclic aryl passes through bicyclic system Any carbon atom or any carbon atom of naphthyl or azulenyl ring that part is contained within are connected to parent molecular moiety.Bicyclic aryl Monocyclic cycloalkyl or monocyclic heterocycles base section are condensed optionally by one or two oxos and/or thia substituent group.Bicyclic aryl Representative example includes but is not limited to azulenyl, naphthyl, indane -1- bases, indane -2- bases, indane -3- bases, indane -4- Base, 2,3- indoline -4- bases, 2,3- indoline -5- bases, 2,3- indoline -6- bases, 2,3- indoline -7- bases, Indenes -1- bases, indenes -2- bases, indenes -3- bases, indenes -4- bases, dihydronaphthalene -2- bases, dihydronaphthalene -3- bases, dihydronaphthalene -4- bases, dihydronaphthalene -1- Base, 5,6,7,8- naphthane -1- bases, 5,6,7,8- naphthane -2- bases, 2,3- Dihydrobenzofuranes -4- bases, 2,3- dihydrobenzos Dioxane between furans -5- bases, 2,3- Dihydrobenzofuranes -6- bases, 2,3- Dihydrobenzofuranes -7- bases, benzo [d] [1,3] Amylene -4- bases, benzo [d] [1,3] dioxole -5- bases, the dilute -2- ketone -5- bases of 2H- colors, the dilute -2- ketone -6- of 2H- colors Dilute -2- ketone -7- the bases of base, 2H- colors, the dilute -2- ketone -8- bases of 2H- colors, isoindoline -1,3- diketone -4- bases, isoindoline -1,3- two Ketone -5- bases, 1-Indanone -4- bases, 1-Indanone -5- bases, 1-Indanone -6- bases, 1-Indanone -7- bases, 2,3- dihydrobenzos [b] [1,4] diox -5- bases, 2,3- dihydrobenzos [b] [1,4] diox -6- bases, 2H- benzos [b] [1,4] oxazines 3 (4H) -one - 5- bases, 2H- benzos [b] [1,4] oxazines 3 (4H) -one -6- bases, 2H- benzos [b] [1,4] oxazines 3 (4H) -one -7- bases, 2H- benzene And [b] [1,4] oxazines 3 (4H) -one -8- bases, benzo [d] oxazines -2 (3H) -one -5- bases, benzo [(3H) -one -6- of d] oxazines -2 Base, benzo [d] oxazines -2 (3H) -one -7- bases, benzo [d] oxazines -2 (3H) -one -8- bases, quinazoline -4 (3H) -one -5- bases, Quinazoline -4 (3H) -one -6- bases, quinazoline -4 (3H) -one -7- bases, quinazoline -4 (3H) -one -8- base, quinoxalines -2 (1H) - (1H) -one -8- bases of -2 (1H) -one -7- base, quinoxalines of -2 (1H) -one -6- base, quinoxalines of ketone -5- base, quinoxalines -2, benzo [d] thiazole -2 (3H) -one -4- bases, benzo [d] thiazole -2 (3H) -one -5- bases, benzo [d] thiazole -2 (3H) -one -6- bases and benzene And [d] thiazole -2 (3H) -one -7- bases.In certain embodiments, bicyclic aryl be fused to 5 or 6 unit monocycle cycloalkyl, 5 or (i) naphthyl or (ii) benzyl ring of 6 unit monocycle cycloalkenyl groups or 5 or 6 unit monocycle heterocyclic radicals, wherein the cycloalkyl for condensing, cycloalkenyl group The substituent group of oxo or thia independently optionally is by one or two with heterocyclyl groups.

Term " aryl alkyl " used herein or for " alkylaryl " refers to by alkyl group defined herein It is connected to the aromatic yl group defined herein of parent molecular moiety.The representative example of aryl alkyl includes but is not limited to benzyl Base, 2- phenylethyls, 3- phenyl propyls and 2- naphthalene -2- base ethyls.

Term " cycloalkyl " used herein refers to monocyclic or bicyclic cycloalkyl loop systems.Single loop system is to contain 3 to 8 The cyclic hydrocarbon group of carbon atom, wherein this group can be saturated or unsaturated, but is not aromatics.In some embodiment party In case, group of naphthene base is fully saturated.The example of monocyclic cycloalkyl includes cyclopropyl, cyclobutyl, cyclopenta, cyclopentene Base, cyclohexyl, cyclohexenyl group, suberyl and cyclooctyl.Bicyclic cycloalkyl loop systems be bridge joint it is monocyclic or condense it is bicyclic.Bridge What is connect is monocyclic containing monocyclic cycloalkyl ring, wherein two monocyclic non-adjacent carbon atoms are by one to three Asia of extra carbon atom Alkyl bridge meets (that is ,-(CH₂)_wThe bridge joint group of-form, wherein w is 1,2 or 3).The representative example of bicyclic system include but It is not limited to bicyclic [3.1.1] heptane, bicyclic [2.2.1] heptane, bicyclic [2.2.2] octane, bicyclic [3.2.2] nonane, bicyclic [3.3.1] nonane and bicyclic [4.2.1] nonane.Condensed-bicyclic alkyl ring system contains and is fused to phenyl, monocyclic cycloalkyl, list The monocyclic cycloalkyl ring of ring cycloalkenyl group, monocyclic heterocycles base or bicyclic heteroaryl.Bridging or the bicyclic cycloalkyl for condensing pass through monocyclic Any carbon atom that cycloalkyl ring is contained within is connected to parent molecular moiety.Group of naphthene base independently optionally is by one or two The substituent group of oxo or thia.In certain embodiments, the bicyclic cycloalkyl for condensing is to be fused to benzyl ring, 5 or 6 yuan of lists 5 or 6 unit monocycle cycloalkanes of the unit monocycle heterocyclic radical of ring cycloalkyl, 5 or 6 unit monocycles cycloalkenyl group, 5 or 6 or 5 or 6 unit monocycle heteroaryls Basic ring, wherein the bicyclic cycloalkyl for condensing optionally independently is the substituent group of oxo or thia by one or two.

Term " heteroaryl " used herein refers to bicyclic heteroaryl or bicyclic system containing at least one hetero-aromatic ring.It is single Ring heteroaryl can be 5 or 6 yuan of rings.5 yuan of rings by two double bonds and one, two, three or four nitrogen-atoms and an optional oxygen or Sulphur atom is constituted.6 yuan of rings are made up of three double bonds and one, two, three or four nitrogen-atoms.5 or 6 unit's heteroaryls are by heteroaryl Any carbon atom or any nitrogen-atoms for containing are connected to parent molecular moiety.The representative example of bicyclic heteroaryl include but not It is limited to furyl, imidazole radicals, isoxazolyls, isothiazolyl, oxadiazolyl, oxazolyls, pyridine radicals, pyridazinyl, pyrimidine radicals, pyrazine Base, pyrazolyl, pyrrole radicals, tetrazole radical, thiadiazolyl group, thiazolyl, thienyl, triazolyl and triazine radical.Bicyclic heteroaryl is by thick Close the bicyclic heteroaryl composition of phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocycles base or bicyclic heteroaryl.It is bicyclic miscellaneous The fused cycloalkyl or heterocyclyl moieties of aromatic yl group independently optionally are the substituent group of oxo or thia by one or two.When When bicyclic heteroaryl contains the cycloalkyl, cycloalkenyl group or the heterocyclic ring that condense, then bicyclic heteroaryl group is by bicyclic system Any carbon or nitrogen-atoms that monocyclic heteroaryl moiety is contained within are connected to parent molecular moiety.When bicyclic heteroaryl is to be fused to benzene During the bicyclic heteroaryl of basic ring, then bicyclic heteroaryl group is connected to mother by any carbon atom or nitrogen-atoms in bicyclic system Body molecular moiety.The representative example of bicyclic heteroaryl includes but is not limited to benzimidazolyl, benzofuranyl, benzothiophene Base, Ben Bing oxadiazolyl, benzo oxa- thia di azoly, benzothiazolyl, cinnolines base, 5,6- EEDQ -2- bases, 5,6- bis- Hydrogen isoquinoline -1- bases, furopyridyl, indazolyl, indyl, isoquinolyl, naphthyridines base, quinolyl, purine radicals, 5,6,7, 8- tetrahydroquinoline -2- bases, 5,6,7,8- tetrahydroquinoline -3- bases, 5,6,7,8- tetrahydroquinoline -4- bases, 5,6,7,8- Tetrahydroisoquinoli-s Quinoline -1- bases, thienopyridine base, 4,5,6,7- tetrahydro benzos [c] [1,2,5] oxadiazolyls and 6,7- dihydrobenzos [c] [1,2, 5] oxadiazoles -4 (5H) -one bases.In certain embodiments, the bicyclic heteroaryl for condensing is to be fused to benzyl ring, 5 or 6 yuan of lists 5 or 6 unit monocycle heteroaryls of the unit monocycle heterocyclic radical of ring cycloalkyl, 5 or 6 unit monocycles cycloalkenyl group, 5 or 6 or 5 or 6 unit monocycle heteroaryls Basic ring, wherein the cycloalkyl for condensing, cycloalkenyl group and heterocyclyl groups independently optionally are the base of oxo or thia by one or two Group's substitution.

Term " heteroaryl alkyl " used herein and "-miscellaneous alkyl aryl " refer to by alkyl group defined herein It is connected to the heteroaryl defined herein of parent molecular moiety.The representative example of heteroaryl alkyl includes but is not limited to furan Mutter -3- ylmethyls, 1H- imidazoles -2- ylmethyls, 1H- imidazol-4 yls methyl, 1- (pyridin-4-yl) ethyl, pyridin-3-yl first Base, pyridin-4-yl methyl, pyrimidine -5- ylmethyls, 2- (pyrimidine -2-base) propyl group, thiophene -2- ylmethyls and thiene-3-yl first Base.

Term " heterocyclic radical " used herein refers to monocyclic heterocycles or bicyclic heterocycle.Monocyclic heterocycles are 3,4,5,6 or 7 yuan Ring, containing at least one independently selected from O, N and S hetero atom, its middle ring is saturation or undersaturated, but is not aromatics.3 Or 4 yuan of rings contain 1 hetero atom selected from O, N and S.5 yuan of rings can be selected from O, N containing zero or double bond and one, two or three With the hetero atom of S.6 or 7 yuan of rings contain zero, one or two double bonds and one, two or three hetero atoms selected from O, N and S.It is monocyclic miscellaneous Any carbon atom or any nitrogen-atoms that ring is contained within by monocyclic heterocycles are connected to parent molecular moiety.The representative of monocyclic heterocycles Property example includes but is not limited to azetidinyl, nitrogen heterocyclic heptyl, '-aziridino, Diazesuberane base, 1,3- bis- Evil It is alkyl, 1,3- dioxolane base, 1,3- dithiolanes base, 1,3- dithiane base, imidazolinyl, imidazolidinyl, different Thiazolinyl, isothiazole alkyl, isoxazoline-3-yl, isoxazole alkyl, morpholinyl, oxadiazole quinoline base, oxadiazole alkyl, oxazoline Base, oxazole alkyl, piperazinyl, piperidyl, pyranose, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuran Base, tetrahydro-thienyl, Thiadiazoline base, thiadiazoles alkyl, thiazolinyl, thiazolidinyl, thio-morpholinyl, 1,1- sulfur dioxide For morpholinyl (thiomorpholine sulfone), thiapyran base and trithiane base.Bicyclic heterocycle is to be fused to phenyl, monocyclic cycloalkyl, monocyclic ring The monocyclic heterocycles of alkenyl, monocyclic heterocycles or bicyclic heteroaryl.Bicyclic heterocycle is contained within by the monocyclic heterocycles part of bicyclic system Any carbon atom or any nitrogen-atoms be connected to parent molecular moiety.The representative example of bicyclic heterocyclic radical is included but is not limited to 2,3- Dihydrobenzofuranes -2- bases, 2,3- Dihydrobenzofuranes -3- bases, indoline -1- bases, indoline -2- bases, dihydro Indoles 3- bases, 2,3- dihydrobenzo thiophene -2- bases, decahydroquinolyl, Decahydroisoquinolinpreparation base, octahydro -1H- indyls and octahydro benzene And furyl.Heterocyclyl groups independently optionally are the substituent group of oxo or thia by one or two.In some embodiments In, bicyclic heterocyclic radical is to be fused to the unit monocycle heterocycle of the unit monocycle cycloalkenyl group of benzyl ring, 5 or 6 unit monocycles cycloalkyl, 5 or 6,5 or 6 5 or 6 unit monocycle heterocyclic rings of base or 5 or 6 unit monocycle heteroaryls, wherein bicyclic heterocyclic radical independently optionally is by one or two The substituent group of oxo or thia.

Extention of the present invention can be degradation material, such as polycaprolactone, poly butylene succinate, PLA, poly- Hydroxyalkanoate, aliphatic aromatic copolyesters, polyvinyl alcohol, carbon dioxide copolymer, poly-beta-hydroxy-butyrate, or it is mixed Compound, or its copolymer, degradation material are the ideal carriers of medicine, and phase sustained release position is uniform, and amount is uniform, and slow-release time is long. After degradation material is degradable, medicine is discharged completely, and the difference according to degradation material can continue -1 year 1 week Time, residual epithelium cell is able to more thoroughly remove.After discharging completely, the groove in lens optical area forms similar sharp The structure on right angle side side, while having functions that prevention.When extention does not use degradation material, healing potion can be adopted Coated and modification technique with any surface disclosed in prior art, be fixed to the surface of ring, unlike other are coated, optics District center without healing potion, remove upper cell more targetedly, it is necessary to dosage also accordingly reduce, it is thin to other normal structures Born of the same parents' injury is small.

In another implementation method of the invention, extention and material of main part are selected from hydrophobic type acrylate, acrylic acid Ester hydrogel, silica gel, silicone-hydrogel, fluorine Si acrylate, polystyrene and polymethyl methacrylate, makrolon, poly- silicon Oxygen alkane, or its mixture.

In another implementation method of the invention, the extention material is selected from biodegradable plastic, such as polycaprolactone, Poly butylene succinate, PLA, PHA, aliphatic aromatic copolyesters, polyvinyl alcohol, carbon dioxide copolymerization Thing, poly-beta-hydroxy-butyrate, or its mixture, or its copolymer.

In another implementation method of the invention, extention drug-carrying can carry all kinds of antibiotic, steroidal and resist Scorching medicine and NSAIDs, prevent post-operation inflammatory, and microorganism infection.Antimetabolitas and mitosis can also be carried Inhibitor, the medicine immunotoxin and cytotoxin that suppress inflammatory reaction, suppress the medicine of cell and extracellular matrix adhesion, lure Guided cell apoptosis medicine prevents and treats post gelating time, degradation material come the mitosis for eliminating LEC or suppressing epithelial cell In degradation process, medicine is sustained.

In another implementation method of the invention, extention can be attached with main body by adhesive, adhesive A-cyanoacrylate class adhesive of medical is selected from, but not limited to, such as α-cyanoacrylaten-butyl, alpha-cyanoacrylate is just pungent Ester, isobutyl alpha-cyanoacrylate and its two kinds of components or three kinds of mixtures of component.

In another implementation method of the invention, extention is selected from medical with the adhesive of intraocular lens's main part Silicone adhesive.Such as MED-1131, MED-1137, MED-1511, MED-1540, MED-1555, MED- of Nusil companies 2000th, MED1-4213 and the medical organic silicon adhesive with phase same-action.

In another implementation method of the invention, the present invention prepares the material and the material for preparing main part of extention May be the same or different, selected from the material of main part comprising polymerisable monomer or any suitable main body material of preferred good biocompatibility Material.Wherein, polymerisable monomer be selected from hydrophilic polymerisable monomer or hydrophobic polymerizable monomer, can be monomer homopolymers or The copolymer of various of monomer.May be selected from high-molecular biologic degradation material simultaneously.

In another implementation method of the invention, preparing the material of main part can be, but be not limited only to：It is above-mentioned to be adapted to Manufacture the ophthalmology medical material with appropriate aqueous rate and suitable index of refraction, collagen, hydrogel, the silicon water of micro-incision artificial lens Gel, fluorine Si acrylate, silicone, polystyrene, methyl methacrylate, siloxanes, methylsiloxane, phenyl siloxane, Vinylsiloxane, acrylate radical siloxane, methacrylate radical siloxane, or above-mentioned mixture.

In another implementation method of the invention, hydrogel is selected from, including but not limited to：Collagen, gelatin, angle egg In vain, elastin laminin, vegetable protein, netted scleroprotein and quaternized albumen etc., or poly- polysaccharide, heparin, chondroitin sulfate, hyalomitome Acid, Arabic gum, agar, Irish moss amine, pectin, guar gum and alginate etc., or modified starch, modified cellulose, carboxylic first Base starch, acetic starch, methylcellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, Carboxymethylcellulose calcium etc., or polyvinyl acetate, polymethyl vinyl ether, polyvinyl alcohol, polyethylene glycol, polyoxyethylene, poly- third Acrylamide (PAM), hydrolyzed polyacrylamide (HPAM)), polyvinylpyrrolidone (PVP), polyethyleneimine (PEI), it is or above-mentioned Blend.

In another implementation method of the invention, the material for preparing extention is also selected from biodegradable material Material, including but not limited to polycaprolactone, poly butylene succinate, PLA, PHA, aliphatic aromatic copolymerization Ester, polyvinyl alcohol, carbon dioxide copolymer, poly-beta-hydroxy-butyrate, or its mixture, or its copolymer.

In another implementation method of the invention, extention includes medicine, including steroids and non-hormone resist The mitotic medicine of scorching medicine and broad-spectrum antibacterials and any elimination lens epithelial cells or suppression epithelial cell, such as oxygen Flucloxacillin, ascorbic acid, aspirin, colchicin, lidocaine, nepafenac, ketorolac, Bromfenac, lepirudin 023 ludon, MTX, 5 FU 5 fluorouracil, taxol, adriamycin, daunorubicin, saponaretin, and other known or unknown have The medicine or composition of identity function.

In another implementation method of the invention, extention is ring-type and including sensitising agent.

In another implementation method of the invention, the artificial lens body part of the present invention has at least two sharp edges Edge.

In another implementation method of the invention, in intraocular lens's main part, support loop is put down with intraocular lens optic Face is at an angle；Supporting the proximal end on the rear surface of loop has square edge staircase structural model；Support loop rear surface it is remote There is square edge staircase structural model, wherein the proximal end thickness of surface step formula structure is thick more than far-end after support loop at end Degree.

In another implementation method of the invention, the step of the square edge staircase structural model of surface far-end after support loop Drop is highly 0.1-5 millimeters, preferably 0.1-1 millimeters, more preferably 0.2-0.5 millimeters, wherein surface step formula knot after support loop The proximal end thickness of structure is more than far-end thickness.

In another implementation method of the invention, the platform of the square edge staircase structural model after loop is supported at proximal end surface Rank drop is 0.1-5 millimeters, preferably 0.3-3 millimeters, more preferably 0.5-2 millimeters, wherein surface step formula structure after support loop Proximal end thickness is more than far-end thickness.

According to another preferred embodiment of the invention, optical component and support loop are in intraocular lens's main part An entirety being made up of same material.

According to another preferred embodiment of the invention, the preceding surface of optical component in intraocular lens's main part And/or rear surface includes optical device, such as, selected from aspherical equipment, multifocal point device, double-curved surface equipment, non-dispersive equipment, Become the conventional suitable various equipment in focus device, light filter plant or this area.

According to another preferred embodiment of the invention, supporting the proximal end of loop has open slot.

The invention further relates to prepare medical treatment device（Such as intraocular lens）Method, it comprises the steps：

（A）（Intraocular lens）It is prepared by main part：

1）By above-mentioned main part is prepared for preparing the material of main part；

2）Prepare and contain reeded intraocular lens's main part；

（B）The preparation of the ring of drug containing, sensitising agent and/or fluorescer：

1）Extention is prepared for preparing the material of extention by above-mentioned, it includes medicine, sensitising agent and/or fluorescence Agent,

（C）Optionally, adhesive is added.

In another implementation method of the invention, for the affinity between intraocular implants' phosphor bodies and extention, people Work lens body can carry out activation process, including but not limited to, corona treatment, sided corona treatment, flame treatment, strong Acid treatment, highly basic treatment etc..Or primary coat paint is coated in intraocular lens's body recess, increase extention and intraocular implants The adhesive force of phosphor bodies.

In the methods of the invention, dosage of crosslinking agent is 0.1-20 weight %, the preferably 0.5-15% of polymerisable monomer, especially 1-5%.Ultraviolet absorber consumption is 0-10 weight %, the preferably 0-5% of polymerisable monomer, especially 0-1%.Initiator amount is can 0.01-10 weight %, the preferably 0.01-5% of polymerized monomer, especially 0.05%-1%.

Other optional components that can be used in the present invention include cosolvent, emulsifying agent, hydrophilic coating, load medicine, color masterbatch, crosslinking It is agent, coupling agent, pH adjusting agent, antistatic additive, releasing agent, pigment, filler, dispersant, curing agent, wetting agent, defoamer, ultraviolet Light absorbers, antioxidant, bactericidal agent and stabilizer etc..

The invention further relates in the method for the effects of phototherapy for treating ophthalmology disease of Laser Driven, wherein the method simply uses this The prepared Medical Devices of invention（Artificial lens）Can be carried out.Specifically, for example, having only by of the present invention Sensitising agent artificial lens（Without additionally adding sensitising agent）, under laser equipment, the position for the treatment of needed for irradiation, due to the present invention Prepared Medical Devices have sensitising agent, and sensitising agent is activated, and by producing the cytotoxic active oxygen of tool, or produce high Warm, can kill lens epithelial cells in lens capsule, reach the effect of prevention or treatment After Cataract.

As can be seen here, material of the present invention and the Medical Devices prepared by the present invention thoroughly break away from exogenous sensitising agent （Without taking sensitising agent etc. in advance）, the inventive method need not add any extra reagent（Including sensitising agent）, and with non- The advantage such as invasion, nontoxicity, high efficiency, repeatability.

Brief description of the drawings

Fig. 1 illustrates the plan view of the intraocular lens that extention is annular, wherein（a）It is main body；（b）Annular is attached Plus part.

Fig. 2 illustrates the profile of the intraocular lens that extention is annular.

Fig. 3 illustrates rear surface and its profile that extention is incorporated into intraocular implants' phosphor bodies, wherein Fig. 3（a）Show Example annulus is located at surface after crystal；Fig. 3（b）Illustrate profile of the annulus positioned at surface after crystal.

Fig. 4 illustrates preceding surface and its profile that extention is incorporated into intraocular lens, wherein Fig. 4（a）Illustrate Annulus is located at brilliant body front surface；Fig. 4（b）Illustrate the profile that annulus is located at brilliant body front surface.

Fig. 5 illustrates extention and combines surface and its profile after intraocular implants' phosphor bodies with embedded mode, wherein Fig. 5（a）Illustrate annulus and rear surface is fixed on embedded mode；Fig. 5（b）Illustrate annulus and rear surface is fixed on embedded mode Profile.

Fig. 6 illustrates the circle that extention is shaped as interruption.

Fig. 7 illustrates the sector that extention is shaped as interruption.

Specific embodiment

1. a kind of intraocular lens, it includes

a）Main part；

2., according to the intraocular lens of foregoing item, wherein the main part of intraocular lens passes through physics with extention Mode or chemical mode are combined.

3., according to the intraocular lens of foregoing any one, wherein physics mode is selected from and casts, inlays, bonding, spraying, printing Brush, evaporation.

4., according to the intraocular lens of foregoing any one, wherein chemical mode is selected from substep copolymerization shaping, grafting and modifying.

5. according to the intraocular lens of foregoing any one, wherein the extention is the extention of ring-type.

6. according to the intraocular lens of foregoing any one, wherein the extention is located at intraocular lens's main part Surface afterwards.

7., according to the intraocular lens of foregoing any one, wherein intraocular lens's main part has one or more recessed Groove, extention is embedded into intraocular lens's main part groove.

8. according to the intraocular lens of foregoing any one, wherein the extention has extra load medicine or activity examination The part of agent.

9. according to the intraocular lens of foregoing any one, wherein, surface is convex ball after the optical section of the main part Face and its radius of curvature is in the range of 6.6 millimeters -80.0 millimeters.

10. according to the intraocular lens of foregoing any one, wherein, the curvature on surface after the optical section of the main part Radius is the 17.8%-60.0% of the radius of curvature on the preceding surface of the optical section.

11. according to the intraocular lens of foregoing any one, wherein, the intraocular lens is prepared by materials described below, The material includes the copolymer prepared by the polymerisable monomer copolymerization comprising esters of acrylic acid, wherein comprising acrylate The polymerisable monomer of class includes hydrophilic acrylate's class monomer and hydrophobic acrylic acid's esters monomer, wherein, hydrophily propylene The mol ratio of esters of gallic acid monomer and hydrophobic acrylic acid's esters monomer is 20:80-80:20, preferably 30:70-70:30, more preferably 40:60-60:40, the material has following properties：

12. according to the intraocular lens of foregoing any one, and wherein hydrophilic acrylate's class monomer is selected from has hydrophily The acrylic ester monomer of group, meets following formula：

Wherein, R₁It is H or C_1-6Alkyl, preferably H or CH₃；

13. according to the intraocular lens of foregoing any one, and wherein hydrophobic acrylic acid's esters monomer is selected from has hydrophobicity The acrylic ester monomer of group, meets following formula：

Wherein, R₁It is H or C_1-6Alkyl, preferably H or CH₃；

R₆It is C_6-20Aryl alkyl, or C_6-20Heteroaryl alkyl.

14. are selected from according to the intraocular lens of foregoing any one, wherein hydrophilic acrylate's class monomer：Methacrylic acid Hydroxy methacrylate, Hydroxyethyl Acrylate, hydroxy propyl methacrylate, hydroxypropyl acrylate, vinyl pyrrolidone, metering system Sour ethoxy ethoxyethyl acrylate, ethoxyethoxy ethyl acrylate, ethoxyethyl methacrylates, ethioxy second Ester, methoxyethyl methacrylate, acrylic acid methoxy ethyl ester, dimethacrylate (1,3 butylene glycol) ester, dimethacrylate Glycol ester, polyethylene glycol methacrylate-styrene polymer, polyethylene glycol 200 dimethylacrylate（Such as AGEFLEX PEG200DMA）, polyethylene glycol acrylate, methoxypolyethylene glycol methacrylate, methoxypolyethylene glycol acrylate, first Base glycidyl acrylate, glycidyl acrylate, acrylic acid, methacrylic acid, 2- (trifluoromethyl) acrylic acid, phenyl Acrylic acid, acrylamide, Methacrylamide, N hydroxymethyl acrylamide, N- methylol methacrylamides, or above-mentioned substance Derivative, or above-mentioned substance mixture, preferred hydroxyethyl methacrylate.

15. are selected from methacrylic acid according to the intraocular lens of foregoing any one, wherein hydrophobic acrylic acid's esters monomer Methyl esters, EMA, ethyl acrylate, butyl methacrylate, butyl acrylate, hexyl methacrylate, propylene The own ester of acid, isopropyl methacrylate, isopropyl acrylate, Isobutyl methacrylate, isobutyl acrylate, methacrylic acid The tert-butyl ester, tert-butyl acrylate, EHMA, Isooctyl acrylate monomer, isodecyl acrylate, isodecyl Ester, lauryl methacrylate, lauryl acrylate, octadecyl methacrylate, octadecyl acrylate, methyl-prop Olefin(e) acid -9- anthracenes methyl esters, olefin(e) acid -9- anthracenes methyl esters, cyclohexyl methacrylate, cyclohexyl acrylate, dimethyl aminoethyl Ester, dimethylaminoethyl methacrylate, N, N- dimethylmethacryl amides, N, N- DMAAs, acrylic acid N, N- diethylamino ethyl ester, methacrylic acid N, N- diethylamino ethyl ester, N tert butyl acrylamide, N- tert-butyl group first Base acrylamide, NIPA, N- isopropyl acrylamides, methacrylic acid tetrahydro furfuryl ester, acrylic acid Tetrahydro furfuryl ester, trifluoroethyl methacrylate, acrylic acid trifluoro ethyl ester, Hexafluorobutyl mathacrylate, acrylic acid hexafluoro fourth Ester, 2- perfluoro decyls ethyl acrylate, 2- perfluoro decyls EMA, 2- (perfluoro capryl) ethyl methacrylate Ester, 2- (perfluoro capryl) ethyl propylenes acid esters, methacrylic acid solketal ester, acrylic acid solketal ester, acrylic acid Tetrahydrofuran ester, THFMA, phenyl methacrylate, phenyl acrylate, methacrylic acid phenyl chlorocarbonate, Phenylethyl acrylate, phenoxyethyl methacrylate, acrylate, benzyl methacrylate, acrylic acid Benzyl ester, AAEM, acetoacetyl ethyl acrylate, DAAM, diacetone first Base acrylamide, allyl methacrylate, acrylate, or above-mentioned substance derivative, or above-mentioned substance Mixture, preferably ethyl acrylate, phenoxyethyl acrylate.

16. according to the intraocular lens of foregoing any one, its glass transition temperature（Dry state, is tested by DSC and is obtained）For 10-35 DEG C, more preferably preferably 15-30 DEG C, 20-25 DEG C.

17. according to the intraocular lens of foregoing any one, its elongation at break（Hygrometric state）>180%, its fracture strength（It is wet State）>2.5 MPa.

18. also include at least one medicine, fluorescer according to the intraocular lens of foregoing any one, wherein extention And/or at least one sensitising agent；

19. according to the intraocular lens of foregoing any one, and wherein extention is ring-type and including sensitising agent.

The invention further relates to following technical scheme：

1. the processing method of intraocular lens described in, including but not limited to：Cutting method, compression molding method, injection moulding, centrifugation Casting method, 3D printing method etc..

3. the sterilizing methods of intraocular lens described in, including but not limited to：Moist heat sterilization, irradiation sterilization, oxirane Sterilizing etc..

4. the host polymer material of the ophthalmic medical instrument according to item 1 can be hydrogel.

5. according to the hydrogel material of item 4, including but not limited to：Collagen, gelatin, keratin, elastin laminin, Vegetable protein, netted scleroprotein and quaternized albumen etc., or poly- polysaccharide, heparin, chondroitin sulfate, hyaluronic acid, Arabic gum, Agar, Irish moss amine, pectin, guar gum and alginate etc., or modified starch, modified cellulose, CMS, acetic acid form sediment Powder, methylcellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose calcium Deng, or polyvinyl acetate, polymethyl vinyl ether, polyvinyl alcohol, polyethylene glycol, polyoxyethylene, polyacrylamide (PAM), Hydrolyzed polyacrylamide (HPAM), polyvinylpyrrolidone (PVP), polyethyleneimine (PEI) etc..

6. medicine, sensitising agent and/or fluorescer annular extention area distribution are on crystal optics area periphery, appendix Point cross section proterties is not limited, and can be square, rectangle, trapezoidal or other irregular shapes.

7. the concentration of medicine, sensitising agent and/or fluorescer in extention material（Or mass fraction）Can be reasonable Control, the active oxygen or high temperature heat produced under selected wavelength laser irradiation enough effectively kills diseased region cell, and saves from damage Normal cell is not suffered a loss；Meanwhile, also need to take into account influence of the minimum level reduction sensitising agent to original materials'use performance.

8., according to the ophthalmic medical instrument of item 1, the irradiation of selected wavelength laser can again or repeatedly be received, and often Secondary irradiation sensitising agent can be activated and produce active oxygen or warm high, so that the medicine equipment has can repeat Effect of laser therapy.

The material of main part of embodiment 1 synthesizes

Embodiment 1-6 illustrates the monomer composition of material of main part synthesis, and all embodiments in table 1 are all prepared in the following manner, All monomers are purified through vacuum distillation.In beaker, respectively according to corresponding ratio mix monomer, the addition initiator of washability With the additive such as light absorber, stir and filter, be transferred in special mould.Used in above-mentioned implementation process The various vessel and mould for arriving through over cleaning, drying and will sterilize before using.

To being passed through nitrogen in the monomer solution in mould, and mould sealed under nitrogen protection, then by mould Being put into the water-bath of design temperature carries out polymerisation at least 24 hours, then mould is transferred in the baking oven of design temperature and continues Insulation 24 hours（Note：The design temperature of baking oven should be higher than that the design temperature of water-bath）.The polymer that will be molded in a mold takes out Room temperature is naturally cooled to, or to it cut into the blank of required size and shape while hot, with alcohols solvent in certain temperature Finally be placed in for blank dried under design temperature in vacuum drying chamber by the lower extraction of degree at least 24 hours with removing remaining small molecule Night, you can obtain the material of main part of the present invention.

Embodiment	1	2	3	4	5	6
							EA	70			60.5	26	46
EMA	27.5
							MMA		17.5	97.5
HEMA		80			40	40
							POEA					30
ST				36
							KH570						10
AIBN	0.2	0.15	0.2	0.15	0.12	0.12
							EGDMA	2	2	2	3	3.5	3.5

EA:Ethyl acrylate

EMA:EMA

MMA:Methyl methacrylate

HEMA：Hydroxyethyl methacrylate

POEA：Acrylic acid -2- phenoxy ethyls

ST:Styrene

KH570：3- (methacryloxypropyl) propyl trimethoxy silicane

AIBN:Azodiisobutyronitrile

EGDMA:Ethylene glycol dimethacrylate.

Embodiment extention synthesis mode Monomer Formations

Embodiment 8-13 schematically illustrates the synthesizing formula of ring-type extention material.The molding mode of extention can be selected from cutting Method, cast molding, spraying, method of molding etc..

Embodiment	8	9	10	11	12	13
							EA	70			60.5	26	46
EMA	27.5
							MMA		17.5	97.5
HEMA		80			40	40
							POEA					30
ST				36
							KH570						10
AIBN	0.2	0.15	0.2	0.15	0.12	0.12
							EGDMA	2	2	2	3	3.5	3.5
Purpurin 18	0.01		0.01			0.01
							IR780		0.02			0.02
IR783				0.01

Embodiment 14：Adhesion mode prepares periphery extention intraocular lens

A it is by turning process) using material processing periphery extention intraocular lens's main part prepared by embodiment 1 Processing, is divided into thickness to be about the brilliant base that 3 mm, diameter are about 16 mm prepared polymeric material.In single-point diamond car Bed（OPTOFORM）Machine-shaping intraocular lens, shaping intraocular lens has the main diameter of 6mm, and main body has extention Connected in star, interior edge is 2.2mm away from intraocular lens center, and width is 0.2mm, and depth is the groove of 0.1mm, artificial after shaping The polished dielectric polish of crystalline lens.

B) according to the formula of embodiment 8, the mode being molded in glass plate using material of main part prepares extention material, Extention material mechanical is then processed into 0.2mm wide using cutting method, thickness is the extention of 0.1mm.

C) by step A）The reeded main part of band of preparation uses vacuum plasma machine, 100w under oxygen atmosphere Power under process 1 minute, then in groove coat silicone adhesive MED-2000, by step B) obtained by extention It is embedded into the groove of main part, being placed in makes adhesive fully dry for 3 hours in 60 DEG C of baking ovens, obtains periphery with extention Intraocular lens.

Embodiment 15：Spraying method prepares periphery extention intraocular lens

A it is by turning process) using material processing periphery extention intraocular lens's main part prepared by embodiment 1 Processing, is divided into thickness to be about the brilliant base that 3 mm, diameter are about 16 mm prepared polymeric material.In single-point diamond car Bed（OPTOFORM）Machine-shaping intraocular lens, shaping intraocular lens has the main diameter of 6.5mm, and main body has appendix Divide connected in star, interior edge is 2.1mm away from intraocular lens center, and width is 0.8mm, and depth is the groove of 0.1mm, the people after shaping The polished dielectric polish of work crystalline lens.

B）By step A）The reeded main part of band of preparation uses vacuum plasma machine, 100w under oxygen atmosphere Power under process 1 minute, improve surface cover performance

C）Formula in extention formulation Example 10 is done into pre-polymerization, performed polymer is fitted into spray gun.Intraocular lens's main part Divide carries out covering treatment in addition to groove part.Control spray amount, after being sprayed to performed polymer, solidifies overnight in 90 DEG C of baking ovens, Obtain periphery extention intraocular lens.

Embodiment 16：Casting mode prepares periphery extention intraocular lens

A it is by turning process) using material processing periphery extention intraocular lens's main part prepared by embodiment 1 Processing, is divided into thickness to be about the brilliant base that 3 mm, diameter are about 16 mm prepared polymeric material.In single-point diamond car Bed（OPTOFORM）Machine-shaping intraocular lens, shaping intraocular lens has the main diameter of 6mm, and main body has extention Connected in star, interior edge is 2.1mm away from intraocular lens center, and width is 0.2mm, and depth is the groove of 1mm, the artificial crystalline substance after shaping The polished dielectric polish of shape body.

B）The formula materials in embodiment 10 are done into pre-polymerization under azodiisobutyronitrile initiation, in there-necked flask, 88 DEG C are gathered Close 1 hour, stirring is stopped when system becomes viscous.

C）By step B）Gained performed polymer is expelled to step A by syringe）The groove of intraocular lens's main part It is interior, make to fill up groove, lie in a horizontal plane in solidification in 90 DEG C of vacuum drying ovens and overnight, obtain periphery extention intraocular lens.

Embodiment 17：The preparation of appendix load sharing medicine intraocular lens

A it is by turning process) using material processing periphery extention intraocular lens's main part prepared by embodiment 1 Processing, is divided into thickness to be about the brilliant base that 3 mm, diameter are about 16 mm prepared polymeric material.In single-point diamond car Bed（OPTOFORM）Machine-shaping intraocular lens, shaping intraocular lens has the main diameter of 6.5mm, and main body has appendix Divide connected in star, interior edge is 2.5mm away from intraocular lens center, and width is 0.2mm, and depth is the groove of 0.02mm, after shaping The polished dielectric polish of intraocular lens.

B) Ofloxacin is dissolved into chloroform, is added in the chloroform soln of PLA, concentrate mixed liquor.

C）Step A is injected into by micro syringe after concentration）In the groove of prepared intraocular lens's main part, put In organic solvent in 45 DEG C of vacuum drying oven, is dried, the intraocular lens of periphery appendix load sharing medicine is obtained.

Claims

1. a kind of intraocular lens, it includes

A) main part；

B) one or more extentions, its be located in intraocular lens's main part and with intraocular lens's main part It is connected, extention width is 0.05 to 3.5mm, more preferably preferably 0.1 to 1.5mm, 0.2 to 0.8mm;Extention is thick It is 0.01 to 2mm to spend, preferably 0.01 to 1mm, more preferably 0.01 to 0.7mm,

2., according to the intraocular lens of preceding claims 1, wherein the main part of intraocular lens passes through thing with extention Reason mode or chemical mode are combined.

3. according to the intraocular lens of any one of preceding claims, wherein the extention is located at intraocular lens's main part The rear surface divided.

4., according to the intraocular lens of any one of preceding claims, wherein intraocular lens's main part has one or more Groove, extention is embedded into intraocular lens's main part groove.

5. according to the intraocular lens of any one of preceding claims, wherein the extention has extra load medicine or adds Plus the part of agent.

6. according to the intraocular lens of any one of preceding claims, wherein, surface is convex after the optical section of the main part Shape sphere and its radius of curvature is in the range of 6.6 millimeters -80.0 millimeters.

7. according to the intraocular lens of any one of preceding claims, wherein, the intraocular lens is prepared by materials described below and obtained , the material includes the copolymer prepared by the polymerisable monomer copolymerization comprising esters of acrylic acid, wherein comprising propylene The polymerisable monomer of esters of gallic acid includes hydrophilic acrylate's class monomer and hydrophobic acrylic acid's esters monomer, wherein, hydrophily The mol ratio of acrylic ester monomer and hydrophobic acrylic acid's esters monomer is 20:80-80:20, preferably 30:70-70:30, more It is preferred that 40:60-60:40, the material has following properties：

8., according to the intraocular lens of any one of preceding claims, wherein hydrophilic acrylate's class monomer is selected from hydrophilic The acrylic ester monomer of property group, meets following formula：

Wherein, R₁It is H or C_1-6Alkyl, preferably H or CH₃；

R₂It is straight or branched, saturation or unsaturation C_1-20Alkyl or C_6-20Aryl alkyl, or straight chain or C_6-20Heteroaryl alkyl；

9., according to the intraocular lens of any one of preceding claims, wherein hydrophobic acrylic acid's esters monomer is selected from hydrophobic The acrylic ester monomer of property group, meets following formula：

Wherein, R₁It is H or C_1-6Alkyl, preferably H or CH₃；

R₅It is straight or branched, saturation or unsaturation C_1-20Alkyl or C_6-20Aryl alkyl, or C_6-20Heteroaryl alkyl, or C_6-20 Cycloheteroalkylalkyl or C_3-20Cycloalkyl；

R₆It is C_6-20Aryl alkyl, or C_6-20Heteroaryl alkyl.

10., according to the intraocular lens of any one of preceding claims, wherein extention also includes at least one medicine, fluorescence Agent and/or at least one sensitising agent；